10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2024

OR

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 000-56225

GOODNESS GROWTH HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

British Columbia, Canada	82-3835655
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)
207 South 9th Street, Minneapolis, MN	55402
(Address of principal executive offices)	(Zip Code)

(612) 999-1606

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
None	None	None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   Yes  þ    No  ◻

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).   Yes  þ    No   ◻

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	◻	Accelerated filer	◻
Non-accelerated filer	þ	Smaller reporting company	þ
		Emerging growth company	þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ◻

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   Yes  ◻    No  þ

As of May 3, 2024, the registrant had the following number of shares of each of its classes of registered securities outstanding: Subordinate Voting Shares –111,041,230; Multiple Voting Shares –320,851; and Super Voting Shares – 0.

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED BALANCE SHEETS

(In U.S Dollars, unaudited)

	March 31,		December 31,
	2024		2023
Assets
Current assets:
Cash	$	12,603,903	$	15,964,665
Accounts receivable, net of credit losses of $205,894 and $254,961, respectively		2,753,673		3,086,640
Income tax receivable		12,102,916		12,278,119
Inventory		19,357,250		19,285,870
Prepayments and other current assets		1,046,127		1,336,234
Notes receivable, current		3,750,000		3,750,000
Warrants held		3,265,231		1,937,352
Assets Held for Sale		92,297,445		91,213,271
Total current assets		147,176,545		148,852,151
Property and equipment, net		23,541,445		23,291,183
Operating lease, right-of-use asset		11,118,882		2,018,163
Intangible assets, net		8,513,765		8,718,577
Deposits		533,745		383,645
Total assets	$	190,884,382	$	183,263,719
Liabilities
Current liabilities
Accounts payable and accrued liabilities	$	7,970,158	$	7,674,389
Long-Term debt, current portion		60,896,288		60,220,535
Right of use liability		882,457		890,013
Uncertain tax liability		26,116,000		22,356,000
Liabilities held for sale		88,373,080		88,326,323
Total current liabilities		184,237,983		179,467,260
Right-of-use liability		19,635,409		10,543,934
Other long-term liabilities		176,257		155,917
Convertible debt, net		9,410,053		9,140,257
Total liabilities		213,459,702		199,307,368
Commitments and contingencies (refer to Note 17)
Stockholders’ deficiency
Subordinate Voting Shares ($- par value, unlimited shares authorized; 111,041,230 shares issued and outstanding at March 31, 2024 and 110,007,030 at December 31, 2023)		—		—
Multiple Voting Shares ($- par value, unlimited shares authorized; 320,851 shares issued and outstanding at March 31, 2024 and 331,193 at December 31, 2023)		—		—
Super Voting Shares ($- par value; unlimited shares authorized; 0 shares issued and outstanding at March 31, 2024 and December 31, 2023)		—		—
Additional Paid in Capital		187,564,192		187,384,403
Accumulated deficit		(210,139,512)		(203,428,052)
Total stockholders' deficiency	$	(22,575,320)	$	(16,043,649)
Total liabilities and stockholders' deficiency	$	190,884,382	$	183,263,719

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

2

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS

(In U.S. Dollars, except per share amounts, unaudited)

	Three Months Ended
	March 31,
	2024		2023
Revenue	$	24,087,315	$	19,088,423
Cost of sales
Product costs		12,146,888		9,578,211
Inventory valuation adjustments		(304,000)		(10,000)
Gross profit		12,244,427		9,520,212
Operating expenses:
Selling, general and administrative		7,051,613		7,156,835
Stock-based compensation expenses		179,789		1,675,594
Depreciation		73,547		159,511
Amortization		180,034		159,766
Total operating expenses		7,484,983		9,151,706
Income (loss) from operations		4,759,444		368,506
Other income (expense):
Gain (loss) on disposal of assets		(120,856)		—
Interest expenses, net		(8,722,637)		(7,134,789)
Other income (expenses)		1,317,589		22,313
Other income (expenses), net		(7,525,904)		(7,112,476)
Loss before income taxes		(2,766,460)		(6,743,970)
Current income tax expenses		(3,945,000)		(1,725,000)
Deferred income tax recoveries		—		63,000
Net loss and comprehensive loss		(6,711,460)		(8,405,970)
Net loss per share - basic and diluted	$	(0.05)	$	(0.07)
Weighted average shares used in computation of net loss per share - basic and diluted		143,126,330		128,126,330

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

3

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY)

(In U.S. Dollars, unaudited)

	Common Stock
	SVS			MVS			Super Voting Shares							Total
										Additional Paid-		Accumulated		Stockholders'
	Shares	Amount		Shares	Amount		Shares	Amount		in Capital		Deficit		Equity (deficiency)
Balance, January 1, 2023	86,721,030	$	—	348,642	$	—	65,411	$	—	$	181,321,847	$	(177,880,963)	$	3,440,884
Stock-based compensation	—		—	—		—	—		—		1,675,594		—		1,675,594
Obligation to issue shares	—		—	—		—	—		—		1,221,837		—		1,221,837
Net Loss	—		—	—		—	—		—		—		(8,405,970)		(8,405,970)
Balance at March 31, 2023	86,721,030	$	—	348,642	$	—	65,411	$	—	$	184,219,278	$	(186,286,933)	$	(2,067,655)
Balance, January 1, 2024	110,007,030		—	331,193		—	—		—		187,384,403		(203,428,052)		(16,043,649)
Conversion of MVS shares	1,034,200		—	(10,342)		—	—		—		—		—		—
Stock-based compensation	—		—	—		—	—		—		179,789		—		179,789
Net Loss	—		—	—		—	—		—		—		(6,711,460)		(6,711,460)
Balance at March 31, 2024	111,041,230	$	—	320,851	$	—	—	$	—	$	187,564,192	$	(210,139,512)	$	(22,575,320)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

4

GOODNESS GROWTH HOLDINGS, INC.

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In U.S. Dollars, unaudited)

	For the Three Months Ended March 31,
	2024		2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(6,711,460)	$	(8,405,970)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory valuation adjustments		(304,000)		(10,000)
Depreciation		73,547		159,511
Depreciation capitalized into inventory		560,180		734,087
Non-cash operating lease expense		103,564		206,290
Amortization of intangible assets		180,034		159,766
Amortization of intangible assets capitalized into inventory		24,778		—
Stock-based payments		179,789		1,675,594
Warrants held		(1,327,879)		—
Interest Expense		2,015,889		1,398,848
Deferred income tax		—		(63,000)
Accretion		52,815		394,573
Loss (gain) on disposal of assets		120,856		—
Change in operating assets and liabilities:
Accounts Receivable		348,817		24,448
Prepaid expenses		290,106		513,902
Inventory		299,252		(1,230,547)
Income taxes		175,203		1,807,364
Uncertain tax position liabilities		3,760,000		—
Accounts payable and accrued liabilities		174,340		(1,141,057)
Changes in operating lease liabilities		(168,746)		—
Change in assets and liabilities held for sale		(1,037,417)		(18,767)
Net cash provided by (used in) operating activities		(1,190,332)		(3,794,958)
CASH FLOWS FROM INVESTING ACTIVITIES:
PP&E Additions		(899,264)		(197,827)
Deposits		(150,100)		(522,375)
Net cash provided by (used in) investing activities		(1,049,364)		(720,202)
CASH FLOWS FROM FINANCING ACTIVITIES
Debt principal payments		(1,050,000)		—
Lease principal payments		(71,066)		(288,574)
Net cash provided by (used in) financing activities		(1,121,066)		(288,574)
Net change in cash		(3,360,762)		(4,803,734)
Cash, beginning of period		15,964,665		15,149,333
Cash, end of period	$	12,603,903	$	10,345,599

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

5

GOODNESS GROWTH HOLDINGS, INC.

Notes to Unaudited Condensed Consolidated Financial Statements

1. Description of Business and Summary

Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (formerly, Vireo Health International, Inc.) was incorporated under the Alberta Business Corporations Act on November 23, 2004. The Company was previously listed on the Canadian Securities Exchange (the “CSE”) under ticker symbol “VREO”. On June 9, 2021, the Company changed its name to Goodness Growth Holdings, Inc. and its ticker symbol on the CSE to “GDNS.”

Goodness Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. Goodness Growth operates cannabis cultivation, production, and dispensary facilities in Maryland, Minnesota, and New York, and formerly in Arizona and New Mexico.

While marijuana and CBD-infused products are legal under the laws of several U.S. states (with vastly differing restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. Recently some federal officials have attempted to distinguish between medical cannabis use as necessary, but adult-use as “still a violation of federal law.” At the present time, the distinction between “medical marijuana” and “adult-use marijuana” does not exist under U.S. federal law.

On January 31, 2022, the Company entered into an Arrangement Agreement (the “Arrangement Agreement”) with Verano Holdings Corp. (“Verano”), pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (British Columbia) (the “Arrangement”). Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive 0.22652 of a subordinate voting share of Verano (each a “Verano Subordinate Voting Share”), subject to adjustment as described below (the “Exchange Ratio”), for each Subordinate Voting Share held, and 22.652 Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.

On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the “Notice”) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company’s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of the $14,875,000 termination fee and its transaction expenses. Goodness Growth denies all of Verano’s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported grounds for termination of the Arrangement Agreement.

On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.

On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.

On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano’s compliance with document production.

6

Throughout 2023, the Company served 4 lists of documents, reviewed document production from Verano, and prepared for examinations for discovery.  The Company also prepared materials in anticipation of seeking summary determination of its claim.

Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.

The termination of the Arrangement Agreement gives rise to substantial doubt about the Company’s ability to continue as a going concern. Company management is working with the Company’s lenders, counsel, and other applicable parties to implement a plan to effectively mitigate the conditions giving rise to substantial doubt. Elements of this plan may include, but are not limited to, asset sales, debt restructuring, and capital raises. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, the Company’s continuance as a going concern is dependent on its future profitability and implementation of the aforementioned plan. The Company may not be successful in these efforts.

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 to the Company’s consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the United States Securities and Exchange Commission (“SEC”) on April 1, 2024, (the "Annual Financial Statements"), as amended on April 29, 2024. There have been no material changes to the Company’s significant accounting policies.

Basis of presentation

The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company. The information included in these statements should be read in conjunction with the Annual Financial Statements. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.

7

Basis of consolidation

These unaudited condensed consolidated financial statements include the accounts of the following entities wholly owned, or effectively controlled by the Company during the period ended March 31, 2024:

Name of entity	Place of  incorporation
Vireo Health, Inc.	Delaware, USA
Vireo Health of New York, LLC	New York, USA
Minnesota Medical Solutions, LLC	Minnesota, USA
MaryMed, LLC	Maryland, USA
Vireo of Charm City, LLC	Maryland, USA
Vireo Health of Massachusetts, LLC	Delaware, USA
Mayflower Botanicals, Inc.	Massachusetts, USA
Resurgent Biosciences, Inc.	Delaware, USA
Vireo Health of Puerto Rico, LLC	Delaware, USA
Vireo Health de Puerto Rico, Inc.	Puerto Rico
XAAS Agro, Inc.	Puerto Rico
Vireo Health of Nevada 1, LLC	Nevada, USA
Verdant Grove, Inc.	Massachusetts, USA

The entities listed are wholly owned or effectively controlled by the Company and have been formed or acquired to support the intended operations of the Company, and all intercompany transactions and balances have been eliminated in the Company's unaudited condensed consolidated financial statements. Red Barn Growers, Inc. and all New Mexico assets and liabilities were divested in June of 2023.

Recently adopted accounting pronouncements

None.

Net loss per share

Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, warrants, and restricted stock units.

In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. The Company recorded a net loss for the three month periods ended March 31, 2024, and 2023, presented in these financial statements, and as such there is no difference between the Company’s basic and diluted net loss per share for these periods.

8

The anti-dilutive shares outstanding for the three month period ending March 31, 2024, and 2023 were as follows:

	March 31,
	2024	2023
Stock options	29,945,511	28,566,282
Warrants	19,437,649	3,187,649
RSUs	2,543,011	3,102,765
Convertible debt	71,569,927	—
Total	123,496,098	34,856,696

Revenue Recognition

The Company’s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. Substantially all of the Company’s retail revenue is from the direct sale of cannabis products to adult-use and medical customers.

The following table represents the Company’s disaggregated revenue by source:

	Three Months Ended March 31,
	2024		2023
Retail	$	19,599,440	$	16,471,799
Wholesale		4,487,875		2,616,624
Total	$	24,087,315	$	19,088,423

New accounting pronouncements not yet adopted

ASU 2023-07 In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has not adopted the standard for the interim periods presented herein, but will adopt the standard on or before December 31, 2024. This ASU will result in additional required disclosures when adopted, where applicable.

ASU 2023-09 In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Once adopted, this ASU will result in additional disclosures.

3. Business Combinations and Dispositions

Assets Held for Sale

As of March 31, 2024, the Company identified property and equipment, deposits, and lease assets and liabilities associated with the businesses in New York, Nevada, and Massachusetts with carrying amounts that are expected to be recovered principally through sale or disposal rather than through continuing use. The sale of these assets and liabilities is highly probable, they can be sold in their immediate condition, and the sales are expected to occur within the next twelve months.

9

As such, these assets and liabilities have been classified as “held for sale.” Management does not believe these divestitures represent a strategic shift that has or will have a major effect on an entity’s operations and financial results, and as such, none of these divestitures are considered a discontinued operation. The carrying value of these net assets did not exceed fair value less expected cost to sell, and as such, the Company recorded no impairment loss. Assets and liabilities held for sale are as follows:

Assets held for sale	March 31,		December 31,
	2024		2023
Property and equipment	$	87,333,100	$	86,864,965
Intangible assets		662,500		662,500
Operating lease, right-of-use asset		3,381,612		3,381,612
Deposits		920,233		304,194
Total assets held for sale	$	92,297,445	$	91,213,271
Liabilities held for sale
Right of Use Liability	$	88,373,080	$	88,326,323
Total liabilities held for sale	$	88,373,080	$	88,326,323

Current assets and liabilities held by our New York business have not been classified as held for sale. Pre-tax operating losses attributable to the New York business were $3,698,934 for the three months ended March 31, 2024.

4. Fair Value Measurements

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

Items measured at fair value on a non-recurring basis

The Company’s non-financial assets, such as prepayments and other current assets, long lived assets, including property and equipment and intangible assets, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. No indicators of impairment existed as of March 31, 2024, and therefore no impairment charges were recorded.

The carrying value of the Company’s accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature, and the carrying value of notes receivable, long-term debt, and convertible debt approximates fair value as they bear a market rate of interest.

The carrying value of the Company’s warrants held  utilize Level 3 inputs given there is no market activity for the asset. The inputs used are further described in Note 19.

10

5. Accounts Receivable

Trade receivables are comprised of the following items:

	March 31,		December 31,
	2024		2023
Trade receivable	$	1,862,555	$	2,256,763
Tax withholding receivable		174,660		174,660
Other		716,458		655,217
Total	$	2,753,673	$	3,086,640

Included in the trade receivables, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of  $46,619 and $95,686 respectively. Included in the tax withholding receivable, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of $159,275.

6. Inventory

Inventory is comprised of the following items:

	March 31,		December 31,
	2024		2023
Work-in-progress	$	13,154,921	$	13,058,348
Finished goods		5,318,269		5,278,331
Other		884,060		949,191
Total	$	19,357,250	$	19,285,870

Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following:

	March 31,
	2024		2023
Work-in-progress	$	(188,200)	$	15,072
Finished goods		(115,800)		(25,072)
Total	$	(304,000)	$	(10,000)

7. Prepayments and other current assets

Prepayments and other current assets are comprised of the following items:

	March 31,		December 31,
	2024		2023
Prepaid Insurance	$	641,365	$	806,610
Other Prepaid Expenses		404,762		529,624
Total	$	1,046,127	$	1,336,234

11

8. Property and Equipment, Net

Property and equipment, net consisted of the following:

	March 31,		December 31,
	2024		2023
Land	$	863,105	$	863,105
Buildings and leasehold improvements		15,204,145		15,124,915
Furniture and equipment		7,035,631		7,807,250
Software		39,388		242,204
Vehicles		271,769		284,000
Construction-in-progress		986,391		128,220
Right of use asset under finance lease		7,938,138		7,938,138
		32,338,567		32,387,832
Less: accumulated depreciation		(8,797,122)		(9,096,649)
Total	$	23,541,445	$	23,291,183

For the three months ended March 31, 2024, and 2023, total depreciation on property and equipment was $633,728 and $893,598, respectively. For the three months ended March 31, 2024, and 2023, accumulated amortization of the right of use asset under finance lease amounted to $2,507,998 and $1,934,235, respectively. The right of use asset under finance lease of $7,938,138 consists of leased processing and cultivation premises. The Company capitalized into inventory $560,180 and $734,087 relating to depreciation associated with manufacturing equipment and production facilities for the three months ended March 31, 2024, and 2023, respectively. The capitalized depreciation costs associated are added to inventory and expensed through Cost of Sales Product Cost on the unaudited condensed consolidated statements of net loss and comprehensive loss.

As of March 31, 2024, in conjunction with the Company’s held for sale assessment and disposal of certain long-lived assets, the Company evaluated whether property and equipment showed any indicators of impairment, and it was determined that the recoverable amount of certain net assets was above book value. As a result, the Company recorded no impairment charge (2023 - $0) on property and equipment, net.

9. Leases

Components of lease expenses are listed below:

	March 31,		March 31,
	2024		2023
Finance lease cost
Amortization of ROU assets	$	143,441	$	270,935
Interest on lease liabilities		3,544,177		2,725,966
Operating lease costs		432,444		590,920
Total lease costs	$	4,120,062	$	3,587,821

12

Future minimum lease payments (principal and interest) on the leases are as follows:

	Operating Leases		Finance Leases
	March 31, 2024		March 31, 2024		Total
2024	$	1,673,583	$	10,183,227	$	11,856,810
2025		3,047,603		13,773,155		16,820,758
2026		2,727,346		14,183,661		16,911,007
2027		2,474,144		14,606,527		17,080,671
2028		2,254,049		15,042,128		17,296,177
Thereafter		7,824,515		218,572,918		226,397,433
Total minimum lease payments	$	20,001,240	$	286,361,616	$	306,362,856
Less discount to net present value		(4,750,354)		(192,721,556)		(197,471,910)
Less liabilities held for sale		(3,096,598)		(85,276,482)		(88,373,080)
Present value of lease liability	$	12,154,288	$	8,363,578	$	20,517,866

The Company has entered into various lease agreements for the use of buildings used in production and retail sales of cannabis products.

On February 22, 2024, the Company executed a lease with its landlord on a site for cannabis cultivation and manufacturing facilities. Per the terms of the lease the landlord agreed to provide the Company with $2,000,000 of tenant improvement allowances. Rent payments will not commence until January 1, 2025, at which time monthly base rent will be $82,500. Starting January 1, 2025, the Company has the option to purchase the property. The initial purchase price is $13,000,000 increasing by 3% at the start of each calendar year until the option expires on December 31, 2028. The lease expires on December 31, 2034.

On February 24, 2023, the Company signed the fourth amendment to the existing lease agreements for the cultivation and processing facilities in New York. The amendment provides for additional tenant improvements of $4,000,000 and increases base rent by $50,000 a month.  

Supplemental cash flow information related to leases:

	March 31,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Lease principal payments - finance	$	71,066	$	288,574
Lease principal payments - operating		168,554		—
Non-cash additions to ROU assets		9,270,915		4,054,328
Amortization of operating leases		170,196		309,747

Other information about lease amounts recognized in the financial statements:

	March 31,
	2024		2023
Weighted-average remaining lease term (years) – operating leases	8.08		4.67
Weighted-average remaining lease term (years) – finance leases	16.82		17.57
Weighted-average discount rate – operating leases	8.58	%	15.00	%
Weighted-average discount rate – finance leases	16.21	%	15.33	%

13

10. Goodwill

The following table shows the change in carrying amount of goodwill:

Goodwill - December 31, 2022	$	183,836
Divestitures (Note 3)		(183,836)
Goodwill - December 31, 2023 and March 31, 2024	$	—

The Company has no goodwill as of March 31, 2024. As such, no further impairment testing procedures were performed.

11. Intangibles

Intangible assets are comprised of the following items:

	Licenses & Trademarks
Balance, December 31, 2022	$	8,776,946
Divestitures		(409,239)
Additions		1,090,919
Amortization		(728,419)
Write off		(11,630)
Balance, December 31, 2023	$	8,718,577
Amortization		(204,812)
Balance, March 31, 2024	$	8,513,765

Amortization expense for intangibles was $204,812 and $159,766 during the three months ended March 31, 2024 and 2023, respectively. Amortization expense is recorded in operating expenses on the unaudited condensed consolidated statements of net loss and comprehensive loss.

The Company estimates that amortization expense will be $819,655 per year for the next five fiscal years.

12. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of the following items:

	March 31,		December 31,
	2024		2023
Accounts payable – trade	$	2,111,125	$	1,769,346
Accrued Expenses		4,626,887		4,852,648
Taxes payable		346,450		218,563
Contract liability		885,696		833,832
Total accounts payable and accrued liabilities	$	7,970,158	$	7,674,389

13. Long-Term Debt

During 2017 the Company signed a promissory note payable in the amount of $1,010,000. The note bears interest at a rate of 15% per annum with interest payments required on a monthly basis. In 2019 the Company’s promissory note payable in the amount of $1,010,000 was modified to increase the amount payable to $1,110,000. The Company repaid the note in full during the three months ended March 31, 2024.

On November 19, 2021, the Company signed a promissory note payable in the amount of $2,000,000 in connection with the acquisition of Charm City Medicus, LLC. The note bears an interest rate of 8% per annum with interest payments due

14

on the last day of each calendar quarter. On November 19, 2023, the Company and lender amended the note. Per the terms of the amendment, the interest rate was modified to 15%, and the Company paid off $1,000,000 of principal.  The remaining principal balance of $1,000,000 is due on November 19, 2024, and the note is secured by 25% of the membership interests in Vireo Health of Charm City, LLC.

On March 25, 2021, the Company entered into a credit agreement for a senior secured delayed draw term loan with an aggregate principal amount of up to $46,000,000 (the “Credit Facility”), and executed a draw of $26,000,000 in principal. The unpaid principal amounts outstanding under the Credit Facility bear interest at a rate of (a) the U.S. prime rate plus 10.375%, payable monthly in cash, and (b) 2.75% per annum paid in kind (“PIK”) interest payable monthly. In connection with the Credit Facility, the Company also pays a monthly credit monitoring fee in the amount of $130,400 which is included in interest expense in the consolidated statements of loss and comprehensive loss for the three months ended March 31, 2024 and 2023.The Credit Facility matures on March 31, 2024.

On November 18, 2021, the Company and lenders amended the Credit Facility to provide for an additional loan of $4,200,000 with a cash interest rate of 15% per annum and PIK interest of 2% per annum and a maturity date of November 29, 2024. Obligations under the Credit Facility are secured by substantially all the assets of the Company.

On January 31, 2022, Goodness Growth and certain of its subsidiaries, as borrowers (collectively, “Borrowers”), entered into a Third Amendment to the Credit Facility (the “Third Amendment”) providing for additional delayed draw term loans of up to $55 million (the “Delayed Draw Loans”). The cash interest rate on the Delayed Draw Loans under the Third Amendment is equal to the U.S. prime rate plus 10.375%, with a minimum required rate of 13.375% per annum, in addition to PIK interest of 2.75% per annum.

On March 31, 2023, the Company executed a fifth amendment to its Credit Facility with its senior secured lender, Chicago Atlantic Admin, LLC (the "Agent"), an affiliate of Green Ivy Capital, and a group of lenders. The amended credit facility extends the maturity date on its Delayed Draw Loans to April 30, 2024, through the issuance of 15,000,000 Subordinate Voting Shares in lieu of a cash extension fee. These 15,000,000 shares were valued at $1,407,903 using a fair value per share of $0.094 and considered a deferred financing cost. The fair value per share reflects a 22% discount to the market price at the time of issuance to account for the four-month trading lock-up imposed on the shares. The amendment also provides the Company with reduced cash outlays by eliminating required amortization of the loan, and requires the Company to divest certain assets to improve its liquidity position and financial performance. The Company has the potential to extend the maturity date on its Delayed Draw Loans up to January 31, 2026 with the satisfaction of certain financial performance-related conditions.

Unless otherwise specified, all deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of March 31, 2024, $201,015 (December 31, 2023 - $1,524,531) of deferred financing costs remain unamortized.

The following table shows a summary of the Company’s long-term debt:

	March 31,		December 31,
	2024		2023
Beginning of year	$	60,220,535	$	58,028,604
Principal repayments		(1,050,000)		(2,976,362)
Deferred financing costs		—		(1,407,903)
PIK interest		1,323,516		1,607,032
Amortization of deferred financing costs		402,237		4,969,164
End of period		60,896,288		60,220,535
Less: current portion		60,896,288		60,220,535
Total long-term debt	$	—	$	—

15

As of March 31, 2024, stated maturities of long-term debt were as follows:

2024	$	60,896,288
Total	$	60,896,288

14. Convertible Notes

On April 28, 2023, the Company closed on a new convertible debt facility which enables the Company to access up to $10,000,000 in aggregate principal amount of convertible notes (the “Convertible Notes”). The convertible facility has a term of three years, with an annual interest rate of 12.0%, comprised of 6.0% cash and 6.0% PIK. The initial tranche's principal amount of Convertible Notes outstanding in the amount of $2,000,000, plus all PIK and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to $0.145. For each future tranche advanced, the principal amount of Convertible Notes outstanding, plus all paid-in-kind interest and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to the lesser of $0.145 or a 20.0% premium over the 30-day volume weighted average price of the Company’s Subordinate Voting Shares calculated on the day prior to the date on which each tranche is advanced, if permitted by the Canadian Securities Exchange. The lenders also have the right to advance any remaining undrawn funds on the convertible loan facility to the Company at any time. If the notes are not converted, the outstanding principal amount and unpaid PIK interest is due on April 30, 2026.

During the year ended December 31, 2023, the Company closed eight additional tranches of Convertible Notes, which are convertible into Subordinate Voting Shares at a conversion price of $0.145. Total proceeds received from these tranches amounted to $8,000,000.

In connection with this financing, the Company issued 6,250,000 warrants to purchase Subordinate Voting Shares of the Company to the lenders. These warrants have a five year term, a strike price of $0.145, and were valued at $497,055. The value of these warrants and other legal and administrative expenses amounting to $1,346,793 are treated as deferred financing costs. All deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of  March 31, 2024 $967,587 (December 31, 2023 - $1,083,697) of deferred financing costs remain unamortized.

The following table shows a summary of the Company’s convertible debt:

	March 31,		December 31,
	2024		2023
Beginning of year	$	9,140,257	$	—
Proceeds		—		10,000,000
Deferred financing costs		—		(1,346,793)
PIK interest		153,686		223,954
Amortization of deferred financing costs		116,110		263,096
End of year	$	9,410,053		9,140,257
Less: current portion		—		—
Total convertible debt	$	9,410,053	$	9,140,257

16

15. Stockholders’ Equity

Shares

The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of March 31, 2024. The liquidation and dividend rights are identical among shares equally in the Company’s earnings and losses on an as converted basis.

	Par Value	Authorized	Voting Rights
Subordinate Voting Share (“SVS”)	—	Unlimited	1 vote for each share
Multiple Voting Share (“MVS”)	—	Unlimited	100 votes for each share
Super Voting Share	—	Unlimited	1,000 votes for each share

Subordinate Voting Shares

Holders of Subordinate Voting Shares are entitled to one vote in respect of each Subordinate Voting Share held.

Multiple Voting Shares

Holders of Multiple Voting Shares are entitled to one hundred votes for each Multiple Voting Share held.

Multiple Voting Shares each have the restricted right to convert to one hundred Subordinate Voting Shares subject to adjustments for certain customary corporate changes.

Super Voting Shares

Holders of Super Voting Shares are entitled to one thousand votes per Super Voting Share. Each Super Voting share is convertible into one Multiple Voting Share.

Shares Issued

During the three months ended March 31, 2024, 10,342 Multiple Voting Shares were redeemed for 1,034,200 Subordinate Voting Shares.

16. Stock-Based Compensation

Stock Options

In January 2019, the Company adopted the 2019 Equity Incentive Plan under which the Company may grant incentive stock option, restricted shares, restricted share units, or other awards. Under the terms of the plan, a total of ten percent of the number of shares outstanding assuming conversion of all super voting shares and multiple voting shares to subordinate voting shares are permitted to be issued. The exercise price for incentive stock options issued under the plan will be set by the committee but will not be less 100% of the fair market value of the Company’s shares on the date of grant. Incentive stock options have a maximum term of 10 years from the date of grant. The incentive stock options vest at the discretion of the Board of Directors.

17

Options granted under the equity incentive plan were valued using the Black-Scholes option pricing model with the following weighted average assumptions:

	March 31,		March 31,
	2024		2023
Risk-Free Interest Rate	N/A		3.84	%
Weighted Average Exercise Price	N/A	$	0.28
Weighted Average Stock Price	N/A	$	0.17
Expected Life of Options (years)	N/A		5.85
Expected Annualized Volatility	N/A	%	100.00	%
Grant Fair Value	N/A	$	0.13
Expected Forfeiture Rate	N/A		N/A
Expected Dividend Yield	N/A		N/A

Stock option activity for the three months ended March 31, 2024, and for the year ended December 31, 2023, is presented below:

		Weighted Average		Weighted Avg.
	Number of Options	Exercise Price		Remaining Life
Balance, December 31, 2022	23,547,558	$	0.66	7.30
Forfeitures	(4,137,079)		0.82	—
Granted	10,558,845		0.25	6.42
Balance, December 31, 2023	29,969,324	$	0.50	6.18
Forfeitures	(23,813)		1.19	—
Options Outstanding at March 31, 2024	29,945,511	$	0.50	5.93
Options Exercisable at March 31, 2024	24,596,552	$	0.42	5.53

During the three month periods ended March 31, 2024 and 2023, the Company recognized $86,732 and $1,399,258 in stock-based compensation relating to stock options, respectively. As of March 31, 2024, the total unrecognized compensation costs related to unvested stock options awards granted was $416,563. In addition, the weighted average period over which the unrecognized compensation expense is expected to be recognized is approximately 1.7 years. The total intrinsic value of stock options outstanding and exercisable as of March 31, 2024, was $3,388,310 and $2,973,949, respectively.

The Company does not estimate forfeiture rates when calculating compensation expense. The Company records forfeitures as they occur.

Warrants

Subordinate Voting Share (SVS) warrants entitle the holder to purchase one subordinate voting share of the Company. Multiple Voting Share (MVS) warrants entitle the holder to purchase one multiple voting share of the Company.

A summary of the warrants outstanding is as follows:

	Number of	Weighted Average		Weighted Average
SVS Warrants	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	150,000	$	1.49	2.00
Granted	16,250,000		0.20	5.00
Warrants outstanding at December 31, 2023	16,400,000	$	0.21	4.57
Granted	—		—	—
Warrants outstanding at March 31, 2024	16,400,000	$	0.21	4.32
Warrants exercisable at March 31, 2024	16,400,000	$	0.21	4.32

18

	Number of	Weighted Average		Weighted Average
SVS Warrants Denominated in C$	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	3,037,649	$	3.50	3.23
Granted	—		—	—
Warrants outstanding at December 31, 2023	3,037,649	$	3.50	2.23
Granted	—		—	—
Warrants outstanding at March 31, 2024	3,037,649	$	3.50	1.98
Warrants exercisable at March 31, 2024	3,037,649	$	3.50	1.98

During the three months ended March 31, 2024, and 2023, $0 in stock-based compensation expense was recorded in connection with outstanding warrants.

Restricted Stock Units (“RSUs”)

The expense associated with RSUs is based on the closing share price of the Company’s subordinate voting shares on the business day immediately preceding the grant date, adjusted for the absence of future dividends and is amortized on a straight-line basis over the periods during which the restrictions lapse. The Company currently has RSUs that vest over a three year period. The awards are generally subject to forfeiture in the event of termination of employment. During the three months ended March 31, 2024, the Company recognized $93,057 and $276,336, respectively, in stock-based compensation expense related to RSUs.

A summary of RSUs is as follows:

		Weighted Avg.
	Number of Shares	Fair Value
Balance, December 31, 2022	3,221,677	$	0.81
Forfeitures	(678,666)		0.54
Balance, December 31, 2023 and March 31, 2024	2,543,011		0.88
Vested at March 31, 2024	1,025,253	$	0.95

17. Commitments and Contingencies

Legal proceedings

Schneyer

On February 25, 2019, Dr. Mark Schneyer (“Schneyer”) filed a lawsuit in Minnesota District Court, Fourth District (the “Court”), on his own behalf and, derivatively, on behalf of Dorchester Capital, LLC, naming Vireo Health, Inc. (“Vireo U.S.”), Dorchester Management, LLC (“Dorchester Management”), and Dorchester Capital, LLC (“Capital”), as defendants. The essence of the claims made by Schneyer is Vireo U.S. paid an inadequate price for MaryMed, LLC (“MaryMed”), which it purchased it from Capital in 2018, and that the consideration given – shares of preferred stock in Vireo U.S. – was distributed inappropriately by Capital at the direction of Dorchester Management (the managing member of Capital). Schneyer, who is a Class B member of Capital, sought unspecified damages in excess of $50,000 and other relief. Dorchester Management, LLC is an affiliated entity to Vireo U.S. and was previously used as a management company over Dorchester Capital, LLC. It no longer has active operations following Vireo Health, Inc.’s acquisition of MaryMed, LLC in 2018. It is owned and controlled by Kyle E. Kingsley and Amber H. Shimpa, executive officers and directors of Vireo U.S. and the Company.

19

While Vireo U.S. continues to believe that Schneyer’s claims lack merit, it agreed to settle the litigation in April 2023 to avoid the expense, distraction and risk of the pre-trial and trial processes. Entering into this settlement in no way changed the defendants’ position that they did nothing wrong and that the claims were baseless.

Verano

On January 31, 2022, the Company entered into the Arrangement Agreement with Verano, pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a Plan of Arrangement. Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive 0.22652 of a Verano Subordinate Voting Share, subject to adjustment as described below, for each Subordinate Voting Share held, and 22.652 Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.

On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the “Notice”) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company’s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of a $14,875,000 termination fee and its transaction expenses. Goodness Growth denies all of Verano’s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported termination of the Arrangement Agreement, which the Company determined to treat as a repudiation of the Arrangement Agreement.

On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano wrongfully repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.

On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.

On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano’s compliance with document production based upon the Company’s belief that Verano was engaging in tactics to delay the litigation. 

Throughout 2023, the Company served 4 lists of documents, reviewed document production from Verano, and prepared for examinations for discovery.  The Company also prepared materials in anticipation of seeking summary determination of its claim, which it anticipates filing within 30 days.

Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.  The damages sought will be significant and material given that Verano’s breach left the Company in a vulnerable position resulting in the Company being constrained in its ability to fund growth initiatives that were desirable and that its competitors were able to undertake, most notably in Minnesota and New York markets.

Lease commitments

The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2041.

20

18. Selling, General and Administrative Expenses

Selling, general and administrative expenses are comprised of the following items:

	Three Months Ended March 31,
	2024		2023
Salaries and benefits	$	3,512,736	$	3,797,410
Professional fees		1,427,096		890,167
Insurance expenses		569,185		635,439
Marketing		222,014		225,113
Other expenses		1,320,582		1,608,706
Total	$	7,051,613	$	7,156,835

19. Other Income (Expense)

On May 25, 2023, the Company and Grown Rogue International, Inc. (“Grown Rogue”) entered into a strategic agreement whereby Grown Rogue will support Goodness Growth in the optimization of its cannabis flower products. As part of this strategic agreement Grown Rogue granted the Company 8,500,000 warrants to purchase subordinate voting shares of Grown Rogue on October 5, 2023. These warrants were valued at $3,265,231 on March 31, 2024 using a stock price of $0.45, an exercise price of $0.17, an expected life of 4.52 years, an annual risk free rate of 4.21%, and volatility of 100%. The change in fair value relative to December 31, 2023 of $1,327,879 was recorded as other income in the unaudited condensed consolidated statement of loss and comprehensive loss for the three months ended March 31, 2024.

20. Supplemental Cash Flow Information⁽¹⁾

	March 31,		March 31,
	2024		2023
Cash paid for interest	$	6,799,193	$	5,731,120
Cash paid for income taxes		—		—
Change in construction accrued expenses		(121,433)		—
Warrants issued in connection with financing activities		—		—

(1) For supplemental cash flow information related to leases, refer to Note 9.

21. Financial Instruments

Credit risk

Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, accounts receivable, and notes receivable. A small portion of cash is held on hand, from which management believes the risk of loss is remote. Receivables relate primarily to wholesale sales. The Company does not have significant credit risk with respect to customers. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments. The Company has been granted licenses pursuant to the laws of the states of Maryland, Minnesota, and New York with respect to cultivating, processing, and/or distributing marijuana. Presently, this industry is illegal under United States federal law. The Company has adhered, and intends to continue to adhere, strictly to the applicable state statutes in its operations.

Liquidity risk

The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As of March 31, 2024, the Company’s financial liabilities consist of accounts payable, accrued liabilities, debt,

21

and convertible debt. The Company manages liquidity risk by reviewing its capital requirements on an ongoing basis. Historically, the Company’s main source of funding has been additional funding from investors and debt issuances. The Company’s access to financing is always uncertain. There can be no assurance of continued access to significant equity or debt financing.

Legal Risk

Goodness Growth operates in the United States. The U.S. federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the U.S., and a lack of accepted safety for the use of the drug under medical supervision. The U.S. Food and Drug Administration has not approved marijuana as a safe and effective drug for any indication. In the U.S. marijuana is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign currency rates. Given the Company’s financial transactions are rarely denominated in a foreign currency, there is minimal foreign currency risk exposure.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company currently carries variable interest-bearing debt subject to fluctuations in the United States Prime rate. A change of 100 basis points in interest rates during the three months ended March 31, 2024, would have resulted in a corresponding change in the statement of loss and comprehensive loss of $138,570.

22. Related Party Transactions

As of March 31, 2024, and December 31, 2023, there were $0 and $121,846 due to related parties, respectively.

23. Subsequent Events

On April 1, 2024, the Company executed a eighth amendment to its lease with its landlord on its cannabis cultivation and manufacturing facilities located in Johnstown, New York. As part of the eighth amendment to the lease in Johnstown, the Company extended its option to terminate the lease. Written notice of termination now needs to be provided by June 15, 2024. Additionally, the Company has a purchase option to buy the premises for $81,000,000. The purchase option extends through March 27, 2026, and the purchase price increases 3% every six months.

On April 1, 2024, ACE Ventures, LLC (“Ace”), a minority-owned business partnership in the State of New York, and the Company executed a binding term sheet whereby Ace plans to acquire the Company’s subsidiary, Vireo Health of New York (“VireoNY”), pending the satisfaction of closing conditions, including secured capital commitments and regulatory approval. Terms of the transaction include a purchase price between $3.0 and $5.0 million for Vireo Health of New York’s licenses, inventory and assets, as well as either Ace’s assumption of the lease agreement with Innovative Industrial Properties (“IIP”) for the Johnstown, NY cannabis cultivation and manufacturing campus or Ace’s acquisition of this campus. Ace has agreed to take financial responsibility for VireoNY’s operations, including its operating losses, beginning on April 1, 2024. These activities are expected to be supported initially by a $2.5 million unsecured loan from the Company to VireoNY.

22

On May 1, 2024, The Company announced that Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Mr. Rosen, retains his Interim Chief Financial Officer title.

On May 1, 2024, The Company announced that it is in ongoing discussions with its senior secured lender, Chicago Atlantic Admin, LLC, an affiliate of Green Ivy Capital, to finalize a longer-term extension of its credit agreement. While this process remains ongoing, the parties have agreed to a short-term extension of the maturity date on their term loan until June 14, 2024, matching all other terms of the existing agreement.

On May 2, 2024, the Company announced that it has filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. (“Verano”) related to Verano’s wrongful termination of the share exchange agreement (the “Arrangement Agreement”) between the parties pursuant to which Verano agreed to acquire all of the outstanding capital stock of the Company in a transaction announced on February 1, 2022. The Company is seeking substantial damages, specifically US $869.0 million, as well as other costs and legal fees, based on Verano’s breach of contract and of its duty of good faith and honest performance. While the Company’s filing of its application for summary determination reflects its belief that Verano’s defense against its claims of unlawful conduct is without merit, the Company can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.

23

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

You should read the following discussion and analysis of our financial condition and results of operations together with the financial information and the notes thereto included in Part I, Item 1 of this Quarterly Report on Form 10-Q. Some of the information contained in this discussion and analysis or set forth elsewhere in this Quarterly Report on Form 10-Q, including information with respect to our outlook, plans and strategy for our business and potential financing, includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or “forward-looking information” within the meaning of Canadian securities laws. These statements are often identified by the use of words such as “anticipate,” “believe,” “continue,” “remain,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would,” “should,” “potential,” “intention,” “strategy,” “strategic,” “approach,” “subject to,” “possible,” “pending,” “if,” or the negative or plural of these words or similar expressions or variations. Such forward-looking statements and forward-looking information are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results and the timing of certain events to differ materially from future results expressed or implied by the forward-looking statements or forward-looking information. Factors that could cause or contribute to such differences include, but are not limited to, those identified in this Quarterly Report on Form 10-Q and those discussed in the section titled “Risk Factors” set forth in Part I, Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2023, as amended, and in our other SEC and Canadian public filings. Such forward-looking statements reflect our beliefs and opinions on the relevant subject based on information available to us as of the date of this report, and while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events. Furthermore, such forward-looking statements or forward-looking information speak only as of the date of this report. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date of such statements.

Amounts are presented in United States dollars, except as otherwise indicated.

Overview of the Company

Goodness Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. With our core operations strategically located in three limited-license markets through our state-licensed subsidiaries, we cultivate and manufacture cannabis products and distribute these products through our growing network of Green Goods^® and other retail dispensaries we own or operate as well as to third-party dispensaries in the markets in which our subsidiaries hold operating licenses.

The termination of the Arrangement Agreement with Verano (as more fully described in Note 17 – Commitments and Contingencies – of our notes to our consolidated financial statement contained herein) gives rise to substantial doubt about the Company’s ability to continue as a going concern. Company management is working with the Company’s lenders, counsel, and other applicable parties to implement a plan to effectively mitigate the conditions giving rise to substantial doubt. Elements of this plan may include, but are not limited to, asset sales, debt restructuring, and capital raises. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, the Company’s continuance as going concern is dependent on its future profitability and implementation of the aforementioned plan. The Company may not be successful in these efforts.

24

Three months ended March 31, 2024, Compared to Three months ended March 31, 2023

Revenue

We derived our revenue from cultivating, processing, and distributing cannabis products through our eighteen dispensaries in four states and our wholesale sales to third parties in two states. For the three months ended March 31, 2024, 81% of our revenue was generated from retail dispensaries and 19% from the wholesale business. For the three months ended March 31, 2023, 86% of our revenue was generated from retail business and 14% from wholesale business.

For the three months ended March 31, 2024, Minnesota operations contributed approximately 46% of revenues, New York contributed 12%, and Maryland contributed 42%. For the three months ended March 31, 2023, Minnesota operations contributed approximately 56% of revenues, New York contributed 18%, New Mexico contributed 6%, and Maryland contributed 20%.

Revenue for the three-months ended March 31, 2024, was $24,087,315, an increase of $4,998,892 or 26% compared to revenue of $19,088,423 for the three-months ended March 31, 2023. The increase is primarily attributable to increased revenue contributions from the Maryland business driven by the commencement of adult-use sales on July 1, 2023, partially offset by the decrease in New Mexico revenues, which was divested in June of 2023.

Retail revenue for the three months ended March 31, 2024, was $19,599,440 an increase of $3,127,641 or 19% compared to retail revenue of $16,471,799 for the three months ended March 31, 2023, primarily due to increased revenue contributions from the Maryland business driven by the commencement of adult-use sales on July 1, 2023, partially offset by the decrease in New Mexico revenues, which was divested in June of 2023.

Wholesale revenue for the three months ended March 31, 2024, was $4,487,875, an increase of $1,871,251 compared to wholesale revenue of $2,616,624 for the three months ended March 31, 2023. The increase was primarily due to increased revenue contributions from the Maryland business driven by the commencement of adult-use sales on July 1, 2023.

	Three Months Ended
	March 31,
	2024		2023		$Change		% Change
Retail:
MN	$	10,977,089	$	10,718,916	$	258,173	2	%
NY		1,821,269		2,361,942		(540,673)	(23)	%
NM		—		1,052,316		(1,052,316)	(100)	%
MD		6,801,082		2,338,625		4,462,457	191	%
Total Retail	$	19,599,440	$	16,471,799	$	3,127,641	19	%
Wholesale:
MD		3,353,661		1,563,875		1,789,786	114	%
NY		1,134,214		1,052,749		81,465	8	%
Total Wholesale	$	4,487,875	$	2,616,624	$	1,871,251	72	%
Total Revenue	$	24,087,315	$	19,088,423	$	4,998,892	26	%
NY and NM	$	(2,955,483)	$	(4,467,007)	$	1,511,524	(34)	%
Total Revenue excluding NY and NM	$	21,131,832	$	14,621,416	$	6,510,416	45	%
N.M. Not Meaningful

Cost of Goods Sold and Gross Profit

Gross profit reflects total net revenue less cost of goods sold. Cost of goods sold represents the costs attributable to producing bulk materials and finished goods, which includes direct materials, labor, and certain indirect costs such as

25

depreciation, insurance and utilities. Cannabis costs are affected by various state regulations that limit the sourcing and procurement of cannabis product, which may create fluctuations in gross profit over comparative periods as the regulatory environment changes.

Cost of goods sold are determined from costs related to the cultivation and processing of cannabis and cannabis-derived products as well as the cost of finished goods inventory purchased from third parties.

Cost of goods sold for the three months ended March 31, 2024, was $11,842,888, an increase of $2,274,677 compared to the three months ended March 31, 2023, of $9,568,211.

Gross profit for the three months ended March 31, 2024, was $12,244,427, representing a gross margin of 51%. This is compared to gross profit for the three months ended March 31, 2023, of $9,520,212 or a 50% gross margin. The increase was primarily attributable to increased profit and margin contributions in Maryland driven by the commencement of Maryland adult-use sales on July 1, 2023.

We believe our current production capacity has not been fully realized and we expect future gross profits to increase with revenue growth reflective of higher demand, increased product output and new product development. However, we expect gradual price compression as markets mature, which could place downward pressure on our retail and wholesale gross margins.

Total Expenses

Total expenses other than the cost of goods sold consist of selling costs to support customer relationships, marketing, and branding activities. It also includes a significant investment in the corporate infrastructure required to support ongoing business.

Selling costs generally correlate to revenue. In the short-term as a percentage of sales, we expect selling costs to remain relatively flat.  However, as positive regulatory developments in our core markets occur, we expect selling costs as a percentage of sales to decrease via growth in our retail and wholesale channels.

General and administrative expenses also include costs incurred at the corporate offices, primarily related to personnel costs, including salaries, benefits, and other professional service costs, as well as corporate insurance, legal and professional fees associated with being a publicly traded company. We expect general and administrative expenses as a percentage of sales to decrease as we realize revenue growth organically and through positive regulatory developments in our core markets.

Total expenses for the three months ended March 31, 2024, were $7,484,983 a decrease of $1,666,723 compared to total expenses of $9,151,706 for the three months ended March 31, 2023. The decrease in total expenses is primarily attributable to a decrease in salaries and wages and stock-based compensation expense.

Operating Income before Other Income (Expense) and Income Taxes

Operating income before other income (expense) and provision for income taxes for the three months ended March 31, 2024, was $4,759,444 an increase of $4,390,938 compared to operating income of $368,506 for the three months ended March 31, 2023.

Total Other Expense

Total other expense for the three months ended March 31, 2024, was $7,525,904, an increase of $413,428 compared to other expense of $7,112,476 for the three months ended March 31, 2023. This change is primarily attributable to an increased interest expenses partially offset by the gain on warrants held of $1,327,879.

26

Provision for Income Taxes

Income tax expense is recognized based on the expected tax payable on the taxable income for the year, using tax rates enacted or substantively enacted at year-end. For the three months ended March 31, 2024, tax expense totaled $3,945,000 compared to tax expense of $1,662,000 for the three months ended March 31, 2023.

NON-GAAP MEASURES

EBITDA is a non-GAAP measure that does not have a standardized definition under the generally accepted accounting principles in the United States of America (“GAAP”). Total Revenues excluding revenues from states where we have divested operations is also a non-GAAP measure that does not have a standardized definition under GAAP. The following information provides reconciliations of the supplemental non-GAAP financial measure EBITDA presented herein to the most directly comparable financial measures calculated and presented in accordance with GAAP.  Reconciliations of the supplemental non-GAAP financial measure Total Revenues that excludes revenues from states where we have divested operations presented herein to the most directly comparable financial measures calculated in accordance with GAAP can be found in the tables above where the measure appears. We have provided these non-GAAP financial measures, which are not calculated or presented in accordance with GAAP, as supplemental information and in addition to the financial measures that are calculated and presented in accordance with GAAP. These supplemental non-GAAP financial measures are presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the supplemental non-GAAP financial measures presented provide additional perspective and insights when analyzing the core operating performance of the business. This supplemental non-GAAP financial measures should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with, the GAAP financial measures presented.

	Three Months Ended
	March 31,
	2024		2023
Net income (loss)	$	(6,711,460)	$	(8,405,970)
Interest expense, net		8,722,637		7,134,789
Income taxes		3,945,000		1,662,000
Depreciation & Amortization		253,581		319,277
Depreciation and amortization included in cost of goods sold		584,958		734,087
EBITDA (non-GAAP)	$	6,794,716	$	1,444,183

Liquidity, Financing Activities During the Period, and Capital Resources

We are an early-stage growth company. We are generating cash from sales and deploying our capital reserves to acquire and develop assets capable of producing additional revenues and earnings over both the immediate and near term. Capital reserves are for capital expenditures and improvements in existing facilities, product development and marketing, customer, supplier, investor, industry relations, and working capital.

Current management forecasts and related assumptions support the view that we can adequately manage the operational needs of the business.

Credit Facility

During 2017 the Company signed a promissory note payable in the amount of $1,010,000. The note bears interest at a rate of 15% per annum with interest payments required on a monthly basis. In 2019 the Company’s promissory note payable in the amount of $1,010,000 was modified to increase the amount payable to $1,110,000. The Company repaid the note in full during the three months ended March 31, 2024.

On November 19, 2021, the Company signed a promissory note payable in the amount of $2,000,000 in connection with the acquisition of Charm City Medicus, LLC. The note bears an interest rate of 8% per annum with interest payments due on the last day of each calendar quarter. On November 19, 2023, the Company and lender amended the note. Per the terms

27

of the amendment, the interest rate was modified to 15%, and the Company paid off $1,000,000 of principal.  The remaining principal balance of $1,000,000 is due on November 19, 2024, and the note is secured by 25% of the membership interests in Vireo Health of Charm City, LLC.

On March 25, 2021, the Company entered into a credit agreement for a senior secured delayed draw term loan with an aggregate principal amount of up to $46,000,000 (the “Credit Facility”), and executed a draw of $26,000,000 in principal. The unpaid principal amounts outstanding under the Credit Facility bear interest at a rate of (a) the U.S. prime rate plus 10.375%, payable monthly in cash, and (b) 2.75% per annum paid in kind (“PIK”) interest payable monthly. In connection with the Credit Facility, the Company also pays a monthly credit monitoring fee in the amount of $130,400 which is included in interest expense in the consolidated statements of loss and comprehensive loss for the three months ended March 31, 2024 and 2023.The Credit Facility matures on March 31, 2024.

On November 18, 2021, the Company and lenders amended the Credit Facility to provide for an additional loan of $4,200,000 with a cash interest rate of 15% per annum and PIK interest of 2% per annum and a maturity date of November 29, 2024. Obligations under the Credit Facility are secured by substantially all the assets of the Company.

On January 31, 2022, Goodness Growth and certain of its subsidiaries, as borrowers (collectively, “Borrowers”), entered into a Third Amendment to the Credit Facility (the “Third Amendment”) providing for additional delayed draw term loans of up to $55 million (the “Delayed Draw Loans”). The cash interest rate on the Delayed Draw Loans under the Third Amendment is equal to the U.S. prime rate plus 10.375%, with a minimum required rate of 13.375% per annum, in addition to PIK interest of 2.75% per annum.

On March 31, 2023, the Company executed a fifth amendment to its Credit Facility with its senior secured lender, Chicago Atlantic Admin, LLC (the "Agent"), an affiliate of Green Ivy Capital, and a group of lenders. The amended credit facility extends the maturity date on its Delayed Draw Loans to April 30, 2024, through the issuance of 15,000,000 Subordinate Voting Shares in lieu of a cash extension fee. These 15,000,000 shares were valued at $1,407,903 using a fair value per share of $0.094 and considered a deferred financing cost. The fair value per share reflects a 22% discount to the market price at the time of issuance to account for the four-month trading lock-up imposed on the shares. The amendment also provides the Company with reduced cash outlays by eliminating required amortization of the loan, and requires the Company to divest certain assets to improve its liquidity position and financial performance. The Company has the potential to extend the maturity date on its Delayed Draw Loans up to January 31, 2026 with the satisfaction of certain financial performance-related conditions.

Unless otherwise specified, all deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of March 31, 2024, $201,015 (December 31, 2023 - $1,524,531) of deferred financing costs remain unamortized.

Convertible Notes

On April 28, 2023, the Company closed on a new convertible debt facility which enables the Company to access up to $10,000,000 in aggregate principal amount of convertible notes (the “Convertible Notes”). The convertible facility has a term of three years, with an annual interest rate of 12.0%, comprised of 6.0% cash and 6.0% PIK. The initial tranche's principal amount of Convertible Notes outstanding in the amount of $2,000,000, plus all PIK and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to $0.145. For each future tranche advanced, the principal amount of Convertible Notes outstanding, plus all paid-in-kind interest and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to the lesser of $0.145 or a 20.0% premium over the 30-day volume weighted average price of the Company’s Subordinate Voting Shares calculated on the day prior to the date on which each tranche is advanced, if permitted by the Canadian Securities Exchange. The lenders also have the right to advance any remaining undrawn funds on the convertible loan facility to the Company at any time. If the notes are not converted, the outstanding principal amount and unpaid PIK interest is due on April 30, 2026.

28

During the year ended December 31, 2023, the Company closed eight additional tranches of Convertible Notes, which are convertible into Subordinate Voting Shares at a conversion price of $0.145. Total proceeds received from these tranches amounted to $8,000,000.

In connection with this financing, the Company issued 6,250,000 warrants to purchase Subordinate Voting Shares of the Company to the lenders. These warrants have a five year term, a strike price of $0.145, and were valued at $497,055. The value of these warrants and other legal and administrative expenses amounting to $1,346,793 are treated as deferred financing costs. All deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of  March 31, 2024 $967,587 (December 31, 2023 - $1,083,697) of deferred financing costs remain unamortized.

Cash Used in Operating Activities

Net cash used in operating activities was $1.2 million for the three months ended March 31, 2024, a decrease of $2.6 million as compared to $3.8 million for the three months ended March 31, 2023. The decrease is primarily attributed to increased gross profit.

Cash Used in Investing Activities

Net cash used in investing activities was $1.0 million for the three months ended March 31, 2024, an increase of $0.3 million compared to net cash used in investing activities of $0.7 million for the three months ended March 31, 2023. The increase is primarily attributable to increased property, plant, and equipment additions relative to the prior year quarter.

Cash Used in Financing Activities

Net cash used in financing activities was $1.1 million for the three months ended March 31, 2024, a change of $0.8 million as compared to $0.3 million used in financing activities in the three months ended March 31, 2023. The change was principally due to repayment of a $1.0 million promissory note during the three months ended March 31, 2024.

Lease Transactions

As of March 31, 2024, we have entered into lease agreements for the use of buildings used in cultivation, production and/or sales of cannabis products in Maryland, Minnesota, and New York.

The lease agreements for all of the retail space used for our dispensary operations are with third-party landlords and remaining duration ranges from 1 to 6 years. These agreements are short-term facility leases that require us to make monthly rent payments as well as funding common area costs, utilities and maintenance. In some cases, we have received tenant improvement funds to assist in the buildout of the space to meet our operating needs. As of March 31, 2024, we operated 14 retail locations secured under these agreements.

We have also entered into sale and leaseback arrangements for our cultivation and processing facilities in Minnesota and New York with a special-purpose real estate investment trust. These leases are long-term agreements that provide, among other things, funds to make certain improvements to the property that will significantly enhance production capacity and operational efficiency of the facility.

29

Excluding any contracts under one year in duration, the future minimum lease payments (principal and interest) on all our leases are as follows:

	Operating Leases		Finance Leases
	March 31, 2024		March 31, 2024		Total
2023	$	1,673,583	$	10,183,227	$	11,856,810
2024		3,047,603		13,773,155		16,820,758
2025		2,727,346		14,183,661		16,911,007
2026		2,474,144		14,606,527		17,080,671
2027		2,254,049		15,042,128		17,296,177
Thereafter		7,824,515		218,572,918		226,397,433
Total minimum lease payments	$	20,001,240	$	286,361,616	$	306,362,856
Less discount to net present value		(4,750,354)		(192,721,556)		(197,471,910)
Less liabilities held for sale		(3,096,598)		(85,276,482)		(88,373,080)
Present value of lease liability	$	12,154,288	$	8,363,578	$	20,517,866

ADDITIONAL INFORMATION

Outstanding Share Data

As of May 3, 2024, we had 111,362,081 shares issued and outstanding, consisting of the following:

(a)  Subordinate voting shares

111,041,230 shares issued and outstanding. The holders of subordinate voting shares are entitled to receive dividends which may be declared from time to time and are entitled to one vote per share at all shareholder meetings. All subordinate voting shares are ranked equally with regards to the Company’s residual assets. The Company is authorized to issue an unlimited number of no-par value subordinate voting shares.

(b)  Multiple voting shares

320,851 shares issued and outstanding. The holders of multiple voting shares are entitled to one hundred votes per share at all shareholder meetings. Each multiple voting share is exchangeable for one hundred subordinate voting shares. The Company is authorized to issue an unlimited number of multiple voting shares.

Options, Warrants, and Convertible Promissory Notes

As of March 31, 2024, we had 29,945,511 employee stock options outstanding, 2,543,011 RSUs outstanding, 3,037,649 Subordinate Voting Share compensation warrants denominated in C$ related to financing activities, and 16,400,000 Subordinate Voting Share compensation warrants outstanding.

Off-Balance Sheet Arrangements

As of the date of this filing, we do not have any off-balance-sheet arrangements that have, or are reasonably likely to have, a current or future effect on our results of operations or financial condition, including, and without limitation, such considerations as liquidity and capital resources.

Critical Accounting Policies and Estimates

There have been no material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report on Form 10-K for the year ended December 31, 2023, as amended.

30

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Quantitative and qualitative disclosures about market risk have been omitted as permitted under rules applicable to smaller reporting companies.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) are designed to ensure that information required to be disclosed by us in reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the appropriate time periods, and that such information is accumulated and communicated to the Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely discussions regarding required disclosure. We, under the supervisions of and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, have evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2024, and, based on that evaluation, have concluded that the design and operation of our disclosure controls and procedures were effective as of such date.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended March 31, 2024, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II — OTHER INFORMATION

Item 1. Legal Proceedings

We are involved in various regulatory issues, claims and lawsuits arising in the ordinary course of business, none of which, in the opinion of management, is expected to have a material, adverse effect on our results of operations or financial condition. The information contained in Part I, Item 1. Financial Statement and Supplementary Date - Note 17, "Commitments and Contingencies," under the heading "Legal Proceedings," is incorporated by reference into this Item 1.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

No unregistered sales of equity securities or repurchase of equity securities occurred during the three months ended March 31, 2024.

Item 5. Other Information

Insider Trading Arrangements

During the three months ended March 31, 2024, none of our directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934, as amended) adopted, modified or terminated a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K of the Securities Act of 1933).

31

Item 6. Exhibits

Exhibit No.	Description of Exhibit
10.50	Fourth Amendment to the Employment Agreement by and among Goodness Growth Holdings, Inc., Vireo Health, Inc., and Amber Shimpa, dated December 21, 2023 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed January 9, 2024)
10.51	Goodness Growth Holdings, Inc. Nonstatutory Stock Option Agreement for Amber Shimpa dated December 21, 2023 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed January 9, 2024)
10.66	Sixth Amendment to Lease Agreement, dated March 5, 2024, by and between IIP-NY 2 LLC and Vireo Health of New York LLC
10.67	Seventh Amendment to Lease Agreement, dated March 11, 2024, by and between IIP-NY 2 LLC and Vireo Health of New York LLC
31.1	Rule 13a-14(a)/15d-14(a) certification of Chief Executive Officer
31.2	Rule 13a-14(a)/15d-14(a) certification of Interim Chief Financial Officer
32.1	Section 1350 certification, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101	Includes the following financial and related information from Goodness Growth’s Quarterly Report on Form 10-Q as of and for the quarter ended March 31, 2024, formatted in Inline Extensible Business Reporting Language (iXBRL): (1) the Consolidated Balance Sheets, (2) the Consolidated Statements of Income, (3) the Consolidated Statements of Comprehensive Income, (4) the Consolidated Statements of Changes in Stockholders’ Equity, (5) the Consolidated Statements of Cash Flows, and (6) Notes to Consolidated Financial Statements.
104	The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL.

32

SIGNATURES

Pursuant to requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	GOODNESS GROWTH HOLDINGS, INC. (Registrant)
Date: May 7, 2024	By:	/s/ Joshua Rosen
		Name:	Joshua Rosen
		Title:	Chief Executive Officer and Interim Chief Financial Officer

33

EX-10.66

Exhibit 10.66

SIXTH AMENDMENT TO LEASE AGREEMENT

THIS SIXTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into asof March 5, 2024 (the “Amendment Effective Date”), by and between IIP-NY 2 LLC, a Delaware limited liability company (“Landlord”), and Vireo Health of New York, LLC, a New York limited liability company (“Tenant”).

RECITALS

A.WHEREAS, Landlord and Tenant are parties to that certain Lease Agreement dated as of October 23,2017,asamendedby thatcertainFirstAmendmenttoLeaseAgreementdatedasofDecember7,2018,asfurther amended by that certain Second Amendment to Lease Agreement dated as of April 10, 2020, as further amended by thatcertainThirdAmendmenttoLeaseAgreementdatedasofSeptember24,2021,asfurtheramendedbythatcertain Fourth Amendment to Lease Agreement dated as of February 24, 2023, and as further amended by that certain Fifth Amendment to Lease Agreement dated as of October 27, 2023 (collectively, the “Existing Lease”), whereby Tenant leases the premises from Landlord located at 256 County Route 117 in Perth, New York; and

B.WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in the respects and on the conditions hereinafter stated.

AGREEMENT

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, agree as follows:

1.Definitions.For purposes of this Amendment, capitalized terms shall have the meanings ascribed to themin theExisting Leaseunlessotherwisedefinedherein.TheExisting Lease,as amendedby this Amendment, is referred to collectively herein as the “Lease.” From and after the date hereof, the term “Lease,” as used in the Existing Lease, shall mean the Existing Lease, as amended by this Amendment.

2.Roadway and Access Easement; New CC&Rs.Tenant has requested, and Landlord hasagreed, to execute and deliver that certain Easement Agreement in favor of Fulton Solar 1 LLC, Fulton Solar 2 LLC, Fulton Solar 3 LLC and Fulton Solar 4 LLC (collectively, the “Adjacent Solar Tenant”), a copy of which is attached hereto as Exhibit “A” to this Amendment and is hereby incorporated herein by reference (the “Easement”).Tenant acknowledgesandagreesthatuponLandlord’sexecutionoftheEasement:(a)theEasement,includingalloftheterms and conditions set forth therein, shall be deemed to be part of the CC&Rs which Tenant is obligated to comply with atitssolecostandexpensepursuantto

1

Section 13oftheExistingLease,(b)Tenantshallbeobligatedtotimelyfulfill andsatisfyallofLandlord’sobligationsundertheEasementasthoughTenantsigned theEasementasthelandowner of the Property thereunder; (c) any failure by Tenant to satisfy the terms and conditions imposed upon the Landlord and the Premises under the Easement that is not cured within any applicable cure period thereunder shall be deemed a “Default”undertheLease;(d)Tenantshall promptlyprovideLandlordwith copiesofanynoticesofdefaultorany other material communications delivered or received by Tenant in relation to the Easement; and (e) Tenant shall indemnify, save, defend (at Landlord’s option and with counsel reasonably acceptable to Landlord) and hold the Landlord Indemnitees harmless from and against any and all Claims of any kind or nature that arise during or after the Term as a result of Tenant’s failure to satisfy the terms and conditions imposed upon Landlord and the Premises under the Easement.The provisions of Section 2(e) shall survive any termination of the Lease.

3.Broker. Tenant represents and warrants that it has not dealt with any broker or agent in the negotiation for or the obtaining of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord’s optionandwithcounselreasonablyacceptabletoLandlord,atTenant’ssolecostandexpense)andholdharmlessthe LandlordIndemniteesfor,fromandagainstanyandallcostorliabilityforcompensationclaimedbyanysuchbroker or agent employed or engaged by it or claiming to have been employed or engaged by it.

4.Effect of Amendment.Except as modified by this Amendment, the Existing Lease and all the covenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are hereby ratified and affirmed.In the event of any conflict between the terms contained in this Amendment and the Existing Lease, the terms herein contained shall supersede and control the obligations and liabilities of the parties.

5.Successors and Assigns.Each of the covenants, conditions and agreements contained in this Amendmentshallinuretothebenefitofandshallapplytoandbebindinguponthepartiesheretoandtheirrespective heirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees.Nothing in this section shall in any way alter the provisions of the Lease restricting assignment or subletting.

6.Miscellaneous.This Amendment becomes effective only upon execution and delivery hereof by LandlordandTenant.ThecaptionsoftheparagraphsandsubparagraphsinthisAmendmentareinsertedandincluded solelyforconvenienceandshallnotbeconsideredorgivenanyeffectinconstruingtheprovisionshereof.Allexhibits hereto are incorporated herein by reference.Submission of this instrument for examination or signature by Tenant does not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment or otherwise until execution by and delivery to both Landlord and Tenant.

7.Authority.Tenantguarantees,warrantsandrepresentsthattheindividualorindividualssigningthis Amendmenthavethepower,authorityandlegalcapacitytosignthisAmendmentonbehalfofandtobindallentities, corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whose behalf such individual or individuals have signed.

2

8.Counterparts; Facsimile and PDF Signatures.This Amendment may be executed in one or more counterparts,eachofwhich,whentakentogether,shallconstituteoneandthesamedocument.Afacsimileorportable document format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as, an original signature.INWITNESSWHEREOF,LandlordandTenanthaveexecutedthisAmendmentasofthedateandyearfirst above written.

[Signatures omitted]

3

EX-10.67

Exhibit 10.67

SEVENTH AMENDMENT TO LEASE AGREEMENT

THIS SEVENTH AMENDMENT TO LEASE AGREEMENT (this “Amendment”) is entered into as ofMarch 11, 2024 (the “Amendment Effective Date”), by and between IIP-NY 2 LLC, a Delaware limited liabilitycompany(“Landlord”),and Vireo HealthofNewYork,LLC,aNewYorklimited liabilitycompany(“Tenant”).

RECITALS

A.WHEREAS, Landlord and Tenant are parties to that certain Lease Agreement dated as of October23, 2017, as amended by that certain First Amendment to Lease Agreement dated as of December 7, 2018, as furtheramended by that certain Second Amendment to Lease Agreement dated as of April 10, 2020, as further amended bythatcertainThirdAmendmenttoLeaseAgreementdatedasofSeptember24,2021,asfurtheramendedbythatcertainFourth Amendment to Lease Agreement dated as of February 24, 2023, as further amended by that certain FifthAmendment to Lease Agreement dated as of October 27, 2023, and as further amended by that certain SixthAmendment to Lease Agreement dated as of March 5, 2024 (collectively, the “Existing Lease”), whereby Tenantleasesthe premisesfromLandlordlocated at256CountyRoute 117 inPerth,NewYork;and

B.WHEREAS, Landlord and Tenant desire to modify and amend the Existing Lease only in therespectsandonthe conditionshereinafterstated.

AGREEMENT

NOW, THEREFORE, Landlord and Tenant, in consideration of the mutual promises contained herein andfor other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, andintendingtobe legallybound, agree asfollows:

1.Definitions.For purposes of this Amendment, capitalized terms shall have the meanings ascribedto them in the Existing Lease unless otherwise defined herein.The Existing Lease, as amended by this Amendment,is referred to collectively herein as the “Lease.” From and after the date hereof, the term “Lease,” as used in theExisting Lease,shallmeantheExistingLease, asamendedbythisAmendment.

2.Extension of Lease Termination Option.Pursuant to Tenant’s request, Landlord has agreed toextend the notice and termination dates with respect to Tenant’s option to terminate the Lease pursuant to Section 5of the Fifth Amendment to the Lease as noted in the Recitals above. Accordingly, Section 5 of the Fifth AmendmentoftheLeaseisherebydeletedinitsentiretyandreplacedwiththefollowing:

“One-Time Lease Termination Option.So long as there is no

1

material default orany Default that has occurred and is continuing, Tenant shall have a one-timeright,exercisablebywrittennotice(the“Lease Termination Notice”)deliveredtoLandlordonorbeforeApril15,2024(the“Termination Notice Expiration Date”),to terminate the Lease (the “Lease Termination”) effective as of a date specifiedtherein that is on or before April 30, 2024 (the “Lease Termination Date”);provided that, on or prior to the Lease Termination Date: (a) Tenant pays toLandlord the sum of Fourteen Million Dollars ($14,000,000.00) (the “LeaseTermination Fee”);(b)Tenant paysallamountsdueandowingas Rent uptoandthrough theLeaseTermination Date;(c) TenantvacatesandsurrendersthePremisestoLandlordintheconditionrequiredbytheLease;(d)priortotheLeaseTerminationDate,Tenanthasnotsurrendered,terminated,transferredorassigneditsrightsinanypermits,licensesorapprovalsrequiredbytheapplicablestateandlocalauthoritiesfortheoperationofthePremisesasalicensedcannabiscultivation and processing facility, nor has Tenant entered into any contract orotheragreementofanykind withanypartyregardingtheforegoing;and(e)priortotheLeaseTerminationDate,noaffiliateofTenantunderanyAdditionalLeaseAgreement shall have surrendered, terminated, transferred or assigned its rightsinanypermits,licensesorapprovalsrequiredbytheapplicablestateandlocal authoritiesfortheoperationofthepremisesasalicensedcannabiscultivationandprocessingfacility,norhassuchtenantenteredintoanycontractorotheragreement of any kind with any party regarding the foregoing.In the event thatTenant fails to deliver a Lease Termination Notice on or before the TerminationNotice Expiration Date (as the same may be extended pursuant to this Section 5)or otherwise fails to satisfy the requirements of this Section 5 as set forth herein,then Tenant shall be deemed to have waived the right to terminate the Leasepursuant to this Section 5 and the provisions of this Section 5 shall be deemednull, void and of no furtherforce and effect.Tenant agrees to reasonablycooperate with Landlord to transition any necessary utilities or security or otherBuilding systems as reasonably requested by Landlord to ensure adequate safety,ongoing maintenanceandsecurityofthe Premises.”

3.Broker. Tenant represents and warrants that it has not dealt with any broker or agent in thenegotiation for or the obtaining of this Amendment and agrees to reimburse, indemnify, save, defend (at Landlord’soption and with counsel reasonably acceptable to Landlord, at Tenant’s sole cost and expense) and hold harmless theLandlordIndemniteesfor,fromandagainstanyand allcostorliabilityforcompensationclaimedbyanysuchbrokeroragentemployed or engagedbyitor claimingtohave been employedorengagedbyit.

2

4.Effect of Amendment.Except as modified by this Amendment, the Existing Lease and all thecovenants, agreements, terms, provisions and conditions thereof shall remain in full force and effect and are herebyratified and affirmed.In the event of any conflict between the terms contained in this Amendment and the ExistingLease, thetermshereincontained shallsupersedeand controltheobligationsand liabilities oftheparties.

5.Successors and Assigns.Each of the covenants, conditions and agreements contained in thisAmendmentshallinuretothebenefitofandshallapplytoandbebindinguponthepartiesheretoandtheirrespectiveheirs, legatees, devisees, executors, administrators and permitted successors and assigns and sublessees.Nothing inthis section shallinanywayalter the provisionsofthe Leaserestrictingassignmentorsubletting.

6.Miscellaneous.This Amendment becomes effective only upon execution and delivery hereof byLandlordandTenant.ThecaptionsoftheparagraphsandsubparagraphsinthisAmendmentareinsertedandincludedsolelyforconvenienceandshallnotbeconsideredorgivenanyeffectinconstruingtheprovisionshereof.Allexhibitshereto are incorporated herein by reference.Submission of this instrument for examination or signature by Tenantdoes not constitute a reservation of or option for a lease, and shall not be effective as a lease, lease amendment orotherwiseuntilexecutionbyanddeliverytoboth LandlordandTenant.

7.Authority.Tenantguarantees,warrantsandrepresentsthattheindividualorindividualssigningthisAmendmenthavethepower,authorityandlegalcapacitytosignthisAmendmentonbehalfofandtobindallentities,corporations, partnerships, limited liability companies, joint venturers or other organizations and entities on whosebehalfsuchindividualor individualshavesigned.

8.Counterparts; Facsimile and PDF Signatures.This Amendment may be executed in one or morecounterparts,eachofwhich,whentakentogether,shallconstituteoneandthesamedocument.Afacsimileorportabledocument format (PDF) signature on this Amendment shall be equivalent to, and have the same force and effect as,anoriginal signature.

INWITNESSWHEREOF,LandlordandTenanthaveexecutedthisAmendmentasofthedateandyearfirstabovewritten.

[Signatures omitted]

3

EX-31.1

Exhibit 31.1

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joshua Rosen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Goodness Growth Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2024

By:	/s/ Joshua Rosen
	Joshua Rosen
	Chief Executive Officer

EX-31.2

Exhibit 31.2

CERTIFICATION PURSUANT TO

RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,

AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Joshua Rosen, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Goodness Growth Holdings, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 7, 2024

By:	/s/ Joshua Rosen
	Joshua Rosen
	Interim Chief Financial Officer

EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED

PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the report of Goodness Growth Holdings, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned, in the capacities and on the dates indicated below, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Joshua Rosen

Joshua Rosen

Chief Executive Officer and Interim Chief Financial Officer

May 7, 2024

XML

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2024	May 03, 2024
Document and Entity Information
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2024
Document Transition Report	false
Entity File Number	000-56225
Entity Registrant Name	GOODNESS GROWTH HOLDINGS, INC.
Entity Incorporation, State or Country Code	CA
Entity Tax Identification Number	82-3835655
Entity Address, Address Line One	207 South 9th Street
Entity Address, City or Town	Minneapolis
Entity Address State Or Province	MN
Entity Address, Postal Zip Code	55402
City Area Code	(612)
Local Phone Number	999-1606
Title of 12(b) Security	None
No Trading Symbol Flag	true
Security Exchange Name	NONE
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Central Index Key	0001771706
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q1
Amendment Flag	false
Subordinate Voting Shares
Document and Entity Information
Entity Common Stock, Shares Outstanding		111,041,230
Multiple Voting Shares
Document and Entity Information
Entity Common Stock, Shares Outstanding		320,851
Super Voting Shares
Document and Entity Information
Entity Common Stock, Shares Outstanding		0

XML

CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash	$ 12,603,903	$ 15,964,665
Accounts receivable, net of credit losses of $205,894 and $254,961, respectively	2,753,673	3,086,640
Income tax receivable	12,102,916	12,278,119
Inventory	19,357,250	19,285,870
Prepayments and other current assets	1,046,127	1,336,234
Notes receivable, current	3,750,000	3,750,000
Warrants held	3,265,231	1,937,352
Assets Held for Sale	92,297,445	91,213,271
Total current assets	147,176,545	148,852,151
Property and equipment, net	23,541,445	23,291,183
Operating lease, right-of-use asset	11,118,882	2,018,163
Intangible assets, net	8,513,765	8,718,577
Deposits	533,745	383,645
Total assets	190,884,382	183,263,719
Current liabilities
Accounts payable and accrued liabilities	7,970,158	7,674,389
Long-Term debt, current portion	60,896,288	60,220,535
Right of use liability	882,457	890,013
Uncertain tax liability	26,116,000	22,356,000
Liabilities held for sale	88,373,080	88,326,323
Total current liabilities	184,237,983	179,467,260
Right-of-use liability	19,635,409	10,543,934
Other long-term liabilities	176,257	155,917
Convertible debt, net	9,410,053	9,140,257
Total liabilities	213,459,702	199,307,368
Commitments and contingencies (refer to Note 17)
Stockholders' deficiency
Additional Paid in Capital	187,564,192	187,384,403
Accumulated deficit	(210,139,512)	(203,428,052)
Total stockholders' deficiency	(22,575,320)	(16,043,649)
Total liabilities and stockholders' deficiency	190,884,382	183,263,719
Subordinate Voting Shares
Stockholders' deficiency
Common stock
Multiple Voting Shares
Stockholders' deficiency
Common stock
Super Voting Shares
Stockholders' deficiency
Common stock

XML

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Common stock
Accounts receivable, credit losses	$ 205,894	$ 254,961
Subordinate Voting Shares
Common stock
Common stock, authorized	Unlimited
Common stock, issued	111,041,230	110,007,030
Common stock, outstanding	111,041,230	110,007,030
Multiple Voting Shares
Common stock
Common stock, authorized	Unlimited
Common stock, issued	320,851	331,193
Common stock, outstanding	320,851	331,193
Super Voting Shares
Common stock
Common stock, authorized	Unlimited
Common stock, issued	0	0
Common stock, outstanding	0	0

XML

CONSOLIDATED STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
CONSOLIDATED STATEMENTS OF NET LOSS AND COMPREHENSIVE LOSS
Revenue	$ 24,087,315	$ 19,088,423
Cost of sales
Product costs	12,146,888	9,578,211
Inventory valuation adjustments	(304,000)	(10,000)
Gross profit	12,244,427	9,520,212
Operating expenses:
Selling, general and administrative	7,051,613	7,156,835
Stock-based compensation expenses	179,789	1,675,594
Depreciation	73,547	159,511
Amortization	180,034	159,766
Total operating expenses	7,484,983	9,151,706
Income (loss) from operations	4,759,444	368,506
Other income (expense):
Gain (loss) on disposal of assets	(120,856)
Interest expenses, net	(8,722,637)	(7,134,789)
Other income (expenses)	1,317,589	22,313
Other income (expenses), net	(7,525,904)	(7,112,476)
Loss before income taxes	(2,766,460)	(6,743,970)
Current income tax expenses	(3,945,000)	(1,725,000)
Deferred income tax recoveries		63,000
Net loss and comprehensive loss	$ (6,711,460)	$ (8,405,970)
Net loss per share - basic (in dollars per share)	$ (0.05)	$ (0.07)
Net loss per share - diluted (in dollars per share)	$ (0.05)	$ (0.07)
Weighted average shares used in computation of net loss per share - basic (in shares)	143,126,330	128,126,330
Weighted average shares used in computation of net loss per share - diluted (in shares)	143,126,330	128,126,330

XML

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY (DEFICIENCY) - USD ($)	Common stock Subordinate Voting Shares	Common stock Multiple Voting Shares	Common stock Super Voting Shares	Additional Paid In Capital	Accumulated Deficit	Subordinate Voting Shares	Multiple Voting Shares	Super Voting Shares	Total
Balance at the beginning at Dec. 31, 2022				$ 181,321,847	$ (177,880,963)				$ 3,440,884
Balance at the beginning (in shares) at Dec. 31, 2022	86,721,030	348,642	65,411
Stock-based compensation				1,675,594					1,675,594
Obligation to issue shares				1,221,837					1,221,837
Net Loss					(8,405,970)				(8,405,970)
Balance at the end at Mar. 31, 2023				184,219,278	(186,286,933)				(2,067,655)
Balance at the end (in shares) at Mar. 31, 2023	86,721,030	348,642	65,411
Balance at the beginning at Dec. 31, 2023				187,384,403	(203,428,052)				(16,043,649)
Balance at the beginning (in shares) at Dec. 31, 2023	110,007,030	331,193				110,007,030	331,193	0
Conversion of shares (in shares)		(10,342)
Conversion of MVS shares (in shares)	1,034,200
Stock-based compensation				179,789					179,789
Net Loss					(6,711,460)				(6,711,460)
Balance at the end at Mar. 31, 2024				$ 187,564,192	$ (210,139,512)				$ (22,575,320)
Balance at the end (in shares) at Mar. 31, 2024	111,041,230	320,851				111,041,230	320,851	0

XML

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (6,711,460)	$ (8,405,970)
Adjustments to reconcile net loss to net cash used in operating activities:
Inventory valuation adjustments	(304,000)	(10,000)
Depreciation	73,547	159,511
Depreciation capitalized into inventory	560,180	734,087
Non-cash operating lease expense	103,564	206,290
Amortization of intangible assets	180,034	159,766
Amortization of intangible assets capitalized into inventory	24,778
Stock-based payments	179,789	1,675,594
Warrants held	(1,327,879)
Interest Expense	2,015,889	1,398,848
Deferred income tax		(63,000)
Accretion	52,815	394,573
Loss (gain) on disposal of assets	120,856
Change in operating assets and liabilities:
Accounts Receivable	348,817	24,448
Prepaid expenses	290,106	513,902
Inventory	299,252	(1,230,547)
Income taxes	175,203	1,807,364
Uncertain tax position liabilities	3,760,000
Accounts payable and accrued liabilities	174,340	(1,141,057)
Changes in operating lease liabilities	(168,746)
Change in assets and liabilities held for sale	(1,037,417)	(18,767)
Net cash provided by (used in) operating activities	(1,190,332)	(3,794,958)
CASH FLOWS FROM INVESTING ACTIVITIES:
PP&E Additions	(899,264)	(197,827)
Deposits	(150,100)	(522,375)
Net cash provided by (used in) investing activities	(1,049,364)	(720,202)
CASH FLOWS FROM FINANCING ACTIVITIES
Debt principal payments	(1,050,000)
Lease principal payments	(71,066)	(288,574)
Net cash provided by (used in) financing activities	(1,121,066)	(288,574)
Net change in cash	(3,360,762)	(4,803,734)
Cash, beginning of period	15,964,665	15,149,333	$ 15,149,333
Cash, end of period	$ 12,603,903	$ 10,345,599	$ 15,964,665

XML

Description of Business and Summary

3 Months Ended

Mar. 31, 2024

Description of Business and Summary

Description of Business and Summary

1. Description of Business and Summary

Goodness Growth Holdings, Inc. (“Goodness Growth” or the “Company”) (formerly, Vireo Health International, Inc.) was incorporated under the Alberta Business Corporations Act on November 23, 2004. The Company was previously listed on the Canadian Securities Exchange (the “CSE”) under ticker symbol “VREO”. On June 9, 2021, the Company changed its name to Goodness Growth Holdings, Inc. and its ticker symbol on the CSE to “GDNS.”

Goodness Growth is a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. Goodness Growth operates cannabis cultivation, production, and dispensary facilities in Maryland, Minnesota, and New York, and formerly in Arizona and New Mexico.

While marijuana and CBD-infused products are legal under the laws of several U.S. states (with vastly differing restrictions), the United States Federal Controlled Substances Act classifies all “marijuana” as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of safety for the use of the drug under medical supervision. Recently some federal officials have attempted to distinguish between medical cannabis use as necessary, but adult-use as “still a violation of federal law.” At the present time, the distinction between “medical marijuana” and “adult-use marijuana” does not exist under U.S. federal law.

On January 31, 2022, the Company entered into an Arrangement Agreement (the “Arrangement Agreement”) with Verano Holdings Corp. (“Verano”), pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a plan of arrangement (the “Plan of Arrangement”) under the Business Corporations Act (British Columbia) (the “Arrangement”). Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive 0.22652 of a subordinate voting share of Verano (each a “Verano Subordinate Voting Share”), subject to adjustment as described below (the “Exchange Ratio”), for each Subordinate Voting Share held, and 22.652 Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.

On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the “Notice”) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company’s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of the $14,875,000 termination fee and its transaction expenses. Goodness Growth denies all of Verano’s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported grounds for termination of the Arrangement Agreement.

On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.

On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.

On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano’s compliance with document production.

Throughout 2023, the Company served 4 lists of documents, reviewed document production from Verano, and prepared for examinations for discovery.  The Company also prepared materials in anticipation of seeking summary determination of its claim.

Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.

The termination of the Arrangement Agreement gives rise to substantial doubt about the Company’s ability to continue as a going concern. Company management is working with the Company’s lenders, counsel, and other applicable parties to implement a plan to effectively mitigate the conditions giving rise to substantial doubt. Elements of this plan may include, but are not limited to, asset sales, debt restructuring, and capital raises. The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. However, the Company’s continuance as a going concern is dependent on its future profitability and implementation of the aforementioned plan. The Company may not be successful in these efforts.

XML

Summary of Significant Accounting Policies

3 Months Ended

Mar. 31, 2024

Summary of Significant Accounting Policies

Summary of Significant Accounting Policies

2. Summary of Significant Accounting Policies

Significant Accounting Policies

The Company’s significant accounting policies are described in Note 2 to the Company’s consolidated financial statements included in the Annual Report on Form 10-K for the fiscal year ended December 31, 2023, filed with the United States Securities and Exchange Commission (“SEC”) on April 1, 2024, (the "Annual Financial Statements"), as amended on April 29, 2024. There have been no material changes to the Company’s significant accounting policies.

Basis of presentation

The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company. The information included in these statements should be read in conjunction with the Annual Financial Statements. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.

Basis of consolidation

These unaudited condensed consolidated financial statements include the accounts of the following entities wholly owned, or effectively controlled by the Company during the period ended March 31, 2024:

Name of entity	Place of  incorporation
Vireo Health, Inc.	Delaware, USA
Vireo Health of New York, LLC	New York, USA
Minnesota Medical Solutions, LLC	Minnesota, USA
MaryMed, LLC	Maryland, USA
Vireo of Charm City, LLC	Maryland, USA
Vireo Health of Massachusetts, LLC	Delaware, USA
Mayflower Botanicals, Inc.	Massachusetts, USA
Resurgent Biosciences, Inc.	Delaware, USA
Vireo Health of Puerto Rico, LLC	Delaware, USA
Vireo Health de Puerto Rico, Inc.	Puerto Rico
XAAS Agro, Inc.	Puerto Rico
Vireo Health of Nevada 1, LLC	Nevada, USA
Verdant Grove, Inc.	Massachusetts, USA

The entities listed are wholly owned or effectively controlled by the Company and have been formed or acquired to support the intended operations of the Company, and all intercompany transactions and balances have been eliminated in the Company's unaudited condensed consolidated financial statements. Red Barn Growers, Inc. and all New Mexico assets and liabilities were divested in June of 2023.

Recently adopted accounting pronouncements

None.

Net loss per share

Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, warrants, and restricted stock units.

In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. The Company recorded a net loss for the three month periods ended March 31, 2024, and 2023, presented in these financial statements, and as such there is no difference between the Company’s basic and diluted net loss per share for these periods.

The anti-dilutive shares outstanding for the three month period ending March 31, 2024, and 2023 were as follows:

	March 31,
	2024	2023
Stock options	29,945,511	28,566,282
Warrants	19,437,649	3,187,649
RSUs	2,543,011	3,102,765
Convertible debt	71,569,927	—
Total	123,496,098	34,856,696

Revenue Recognition

The Company’s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. Substantially all of the Company’s retail revenue is from the direct sale of cannabis products to adult-use and medical customers.

The following table represents the Company’s disaggregated revenue by source:

	Three Months Ended March 31,
	2024		2023
Retail	$	19,599,440	$	16,471,799
Wholesale		4,487,875		2,616,624
Total	$	24,087,315	$	19,088,423

New accounting pronouncements not yet adopted

ASU 2023-07 In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has not adopted the standard for the interim periods presented herein, but will adopt the standard on or before December 31, 2024. This ASU will result in additional required disclosures when adopted, where applicable.

ASU 2023-09 In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Once adopted, this ASU will result in additional disclosures.

XML

Business Combinations and Dispositions

3 Months Ended

Mar. 31, 2024

Business Combinations and Dispositions

Business Combinations and Dispositions

3. Business Combinations and Dispositions

Assets Held for Sale

As of March 31, 2024, the Company identified property and equipment, deposits, and lease assets and liabilities associated with the businesses in New York, Nevada, and Massachusetts with carrying amounts that are expected to be recovered principally through sale or disposal rather than through continuing use. The sale of these assets and liabilities is highly probable, they can be sold in their immediate condition, and the sales are expected to occur within the next twelve months.

As such, these assets and liabilities have been classified as “held for sale.” Management does not believe these divestitures represent a strategic shift that has or will have a major effect on an entity’s operations and financial results, and as such, none of these divestitures are considered a discontinued operation. The carrying value of these net assets did not exceed fair value less expected cost to sell, and as such, the Company recorded no impairment loss. Assets and liabilities held for sale are as follows:

Assets held for sale	March 31,		December 31,
	2024		2023
Property and equipment	$	87,333,100	$	86,864,965
Intangible assets		662,500		662,500
Operating lease, right-of-use asset		3,381,612		3,381,612
Deposits		920,233		304,194
Total assets held for sale	$	92,297,445	$	91,213,271
Liabilities held for sale
Right of Use Liability	$	88,373,080	$	88,326,323
Total liabilities held for sale	$	88,373,080	$	88,326,323

Current assets and liabilities held by our New York business have not been classified as held for sale. Pre-tax operating losses attributable to the New York business were $3,698,934 for the three months ended March 31, 2024.

XML

Fair Value Measurements

3 Months Ended

Mar. 31, 2024

Fair Value Measurements

Fair Value Measurements

4. Fair Value Measurements

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.

Items measured at fair value on a non-recurring basis

The Company’s non-financial assets, such as prepayments and other current assets, long lived assets, including property and equipment and intangible assets, are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized. No indicators of impairment existed as of March 31, 2024, and therefore no impairment charges were recorded.

The carrying value of the Company’s accounts receivable, accounts payable, and accrued liabilities approximate their fair value due to their short-term nature, and the carrying value of notes receivable, long-term debt, and convertible debt approximates fair value as they bear a market rate of interest.

The carrying value of the Company’s warrants held  utilize Level 3 inputs given there is no market activity for the asset. The inputs used are further described in Note 19.

XML

Accounts Receivable

3 Months Ended

Mar. 31, 2024

Accounts Receivable

Accounts Receivable

5. Accounts Receivable

Trade receivables are comprised of the following items:

	March 31,		December 31,
	2024		2023
Trade receivable	$	1,862,555	$	2,256,763
Tax withholding receivable		174,660		174,660
Other		716,458		655,217
Total	$	2,753,673	$	3,086,640

Included in the trade receivables, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of  $46,619 and $95,686 respectively. Included in the tax withholding receivable, net balance at March 31, 2024, and December 31, 2023, is an allowance for doubtful accounts of $159,275.

XML

Inventory

3 Months Ended

Mar. 31, 2024

Inventory

Inventory

6. Inventory

Inventory is comprised of the following items:

	March 31,		December 31,
	2024		2023
Work-in-progress	$	13,154,921	$	13,058,348
Finished goods		5,318,269		5,278,331
Other		884,060		949,191
Total	$	19,357,250	$	19,285,870

Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable value of inventory is less than the carrying value. Inventory valuation adjustments included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following:

	March 31,
	2024		2023
Work-in-progress	$	(188,200)	$	15,072
Finished goods		(115,800)		(25,072)
Total	$	(304,000)	$	(10,000)

XML

Prepayments and other current assets

3 Months Ended

Mar. 31, 2024

Prepayments and other current assets

Prepayments and other current assets

7. Prepayments and other current assets

Prepayments and other current assets are comprised of the following items:

	March 31,		December 31,
	2024		2023
Prepaid Insurance	$	641,365	$	806,610
Other Prepaid Expenses		404,762		529,624
Total	$	1,046,127	$	1,336,234

XML

Property and Equipment, Net

3 Months Ended

Mar. 31, 2024

Property and Equipment, Net

Property and Equipment, Net

8. Property and Equipment, Net

Property and equipment, net consisted of the following:

	March 31,		December 31,
	2024		2023
Land	$	863,105	$	863,105
Buildings and leasehold improvements		15,204,145		15,124,915
Furniture and equipment		7,035,631		7,807,250
Software		39,388		242,204
Vehicles		271,769		284,000
Construction-in-progress		986,391		128,220
Right of use asset under finance lease		7,938,138		7,938,138
		32,338,567		32,387,832
Less: accumulated depreciation		(8,797,122)		(9,096,649)
Total	$	23,541,445	$	23,291,183

For the three months ended March 31, 2024, and 2023, total depreciation on property and equipment was $633,728 and $893,598, respectively. For the three months ended March 31, 2024, and 2023, accumulated amortization of the right of use asset under finance lease amounted to $2,507,998 and $1,934,235, respectively. The right of use asset under finance lease of $7,938,138 consists of leased processing and cultivation premises. The Company capitalized into inventory $560,180 and $734,087 relating to depreciation associated with manufacturing equipment and production facilities for the three months ended March 31, 2024, and 2023, respectively. The capitalized depreciation costs associated are added to inventory and expensed through Cost of Sales Product Cost on the unaudited condensed consolidated statements of net loss and comprehensive loss.

As of March 31, 2024, in conjunction with the Company’s held for sale assessment and disposal of certain long-lived assets, the Company evaluated whether property and equipment showed any indicators of impairment, and it was determined that the recoverable amount of certain net assets was above book value. As a result, the Company recorded no impairment charge (2023 - $0) on property and equipment, net.

XML

Leases

3 Months Ended

Mar. 31, 2024

Leases

Leases

9. Leases

Components of lease expenses are listed below:

	March 31,		March 31,
	2024		2023
Finance lease cost
Amortization of ROU assets	$	143,441	$	270,935
Interest on lease liabilities		3,544,177		2,725,966
Operating lease costs		432,444		590,920
Total lease costs	$	4,120,062	$	3,587,821

Future minimum lease payments (principal and interest) on the leases are as follows:

	Operating Leases		Finance Leases
	March 31, 2024		March 31, 2024		Total
2024	$	1,673,583	$	10,183,227	$	11,856,810
2025		3,047,603		13,773,155		16,820,758
2026		2,727,346		14,183,661		16,911,007
2027		2,474,144		14,606,527		17,080,671
2028		2,254,049		15,042,128		17,296,177
Thereafter		7,824,515		218,572,918		226,397,433
Total minimum lease payments	$	20,001,240	$	286,361,616	$	306,362,856
Less discount to net present value		(4,750,354)		(192,721,556)		(197,471,910)
Less liabilities held for sale		(3,096,598)		(85,276,482)		(88,373,080)
Present value of lease liability	$	12,154,288	$	8,363,578	$	20,517,866

The Company has entered into various lease agreements for the use of buildings used in production and retail sales of cannabis products.

On February 22, 2024, the Company executed a lease with its landlord on a site for cannabis cultivation and manufacturing facilities. Per the terms of the lease the landlord agreed to provide the Company with $2,000,000 of tenant improvement allowances. Rent payments will not commence until January 1, 2025, at which time monthly base rent will be $82,500. Starting January 1, 2025, the Company has the option to purchase the property. The initial purchase price is $13,000,000 increasing by 3% at the start of each calendar year until the option expires on December 31, 2028. The lease expires on December 31, 2034.

On February 24, 2023, the Company signed the fourth amendment to the existing lease agreements for the cultivation and processing facilities in New York. The amendment provides for additional tenant improvements of $4,000,000 and increases base rent by $50,000 a month.  

Supplemental cash flow information related to leases:

	March 31,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Lease principal payments - finance	$	71,066	$	288,574
Lease principal payments - operating		168,554		—
Non-cash additions to ROU assets		9,270,915		4,054,328
Amortization of operating leases		170,196		309,747

Other information about lease amounts recognized in the financial statements:

	March 31,
	2024		2023
Weighted-average remaining lease term (years) – operating leases	8.08		4.67
Weighted-average remaining lease term (years) – finance leases	16.82		17.57
Weighted-average discount rate – operating leases	8.58	%	15.00	%
Weighted-average discount rate – finance leases	16.21	%	15.33	%

XML

Goodwill

3 Months Ended

Mar. 31, 2024

Goodwill

Goodwill

10. Goodwill

The following table shows the change in carrying amount of goodwill:

Goodwill - December 31, 2022	$	183,836
Divestitures (Note 3)		(183,836)
Goodwill - December 31, 2023 and March 31, 2024	$	—

The Company has no goodwill as of March 31, 2024. As such, no further impairment testing procedures were performed.

XML

Intangibles

3 Months Ended

Mar. 31, 2024

Intangibles

Intangibles

11. Intangibles

Intangible assets are comprised of the following items:

	Licenses & Trademarks
Balance, December 31, 2022	$	8,776,946
Divestitures		(409,239)
Additions		1,090,919
Amortization		(728,419)
Write off		(11,630)
Balance, December 31, 2023	$	8,718,577
Amortization		(204,812)
Balance, March 31, 2024	$	8,513,765

Amortization expense for intangibles was $204,812 and $159,766 during the three months ended March 31, 2024 and 2023, respectively. Amortization expense is recorded in operating expenses on the unaudited condensed consolidated statements of net loss and comprehensive loss.

The Company estimates that amortization expense will be $819,655 per year for the next five fiscal years.

XML

Accounts Payable and Accrued Liabilities

3 Months Ended

Mar. 31, 2024

Accounts Payable and Accrued Liabilities

Accounts Payable and Accrued Liabilities

12. Accounts Payable and Accrued Liabilities

Accounts payable and accrued liabilities are comprised of the following items:

	March 31,		December 31,
	2024		2023
Accounts payable – trade	$	2,111,125	$	1,769,346
Accrued Expenses		4,626,887		4,852,648
Taxes payable		346,450		218,563
Contract liability		885,696		833,832
Total accounts payable and accrued liabilities	$	7,970,158	$	7,674,389

XML

Long-Term Debt

3 Months Ended

Mar. 31, 2024

Long-Term Debt

Long-Term Debt

13. Long-Term Debt

During 2017 the Company signed a promissory note payable in the amount of $1,010,000. The note bears interest at a rate of 15% per annum with interest payments required on a monthly basis. In 2019 the Company’s promissory note payable in the amount of $1,010,000 was modified to increase the amount payable to $1,110,000. The Company repaid the note in full during the three months ended March 31, 2024.

On November 19, 2021, the Company signed a promissory note payable in the amount of $2,000,000 in connection with the acquisition of Charm City Medicus, LLC. The note bears an interest rate of 8% per annum with interest payments due

on the last day of each calendar quarter. On November 19, 2023, the Company and lender amended the note. Per the terms of the amendment, the interest rate was modified to 15%, and the Company paid off $1,000,000 of principal.  The remaining principal balance of $1,000,000 is due on November 19, 2024, and the note is secured by 25% of the membership interests in Vireo Health of Charm City, LLC.

On March 25, 2021, the Company entered into a credit agreement for a senior secured delayed draw term loan with an aggregate principal amount of up to $46,000,000 (the “Credit Facility”), and executed a draw of $26,000,000 in principal. The unpaid principal amounts outstanding under the Credit Facility bear interest at a rate of (a) the U.S. prime rate plus 10.375%, payable monthly in cash, and (b) 2.75% per annum paid in kind (“PIK”) interest payable monthly. In connection with the Credit Facility, the Company also pays a monthly credit monitoring fee in the amount of $130,400 which is included in interest expense in the consolidated statements of loss and comprehensive loss for the three months ended March 31, 2024 and 2023.The Credit Facility matures on March 31, 2024.

On November 18, 2021, the Company and lenders amended the Credit Facility to provide for an additional loan of $4,200,000 with a cash interest rate of 15% per annum and PIK interest of 2% per annum and a maturity date of November 29, 2024. Obligations under the Credit Facility are secured by substantially all the assets of the Company.

On January 31, 2022, Goodness Growth and certain of its subsidiaries, as borrowers (collectively, “Borrowers”), entered into a Third Amendment to the Credit Facility (the “Third Amendment”) providing for additional delayed draw term loans of up to $55 million (the “Delayed Draw Loans”). The cash interest rate on the Delayed Draw Loans under the Third Amendment is equal to the U.S. prime rate plus 10.375%, with a minimum required rate of 13.375% per annum, in addition to PIK interest of 2.75% per annum.

On March 31, 2023, the Company executed a fifth amendment to its Credit Facility with its senior secured lender, Chicago Atlantic Admin, LLC (the "Agent"), an affiliate of Green Ivy Capital, and a group of lenders. The amended credit facility extends the maturity date on its Delayed Draw Loans to April 30, 2024, through the issuance of 15,000,000 Subordinate Voting Shares in lieu of a cash extension fee. These 15,000,000 shares were valued at $1,407,903 using a fair value per share of $0.094 and considered a deferred financing cost. The fair value per share reflects a 22% discount to the market price at the time of issuance to account for the four-month trading lock-up imposed on the shares. The amendment also provides the Company with reduced cash outlays by eliminating required amortization of the loan, and requires the Company to divest certain assets to improve its liquidity position and financial performance. The Company has the potential to extend the maturity date on its Delayed Draw Loans up to January 31, 2026 with the satisfaction of certain financial performance-related conditions.

Unless otherwise specified, all deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of March 31, 2024, $201,015 (December 31, 2023 - $1,524,531) of deferred financing costs remain unamortized.

The following table shows a summary of the Company’s long-term debt:

	March 31,		December 31,
	2024		2023
Beginning of year	$	60,220,535	$	58,028,604
Principal repayments		(1,050,000)		(2,976,362)
Deferred financing costs		—		(1,407,903)
PIK interest		1,323,516		1,607,032
Amortization of deferred financing costs		402,237		4,969,164
End of period		60,896,288		60,220,535
Less: current portion		60,896,288		60,220,535
Total long-term debt	$	—	$	—

As of March 31, 2024, stated maturities of long-term debt were as follows:

2024	$	60,896,288
Total	$	60,896,288

XML

Convertible Debt

3 Months Ended

Mar. 31, 2024

Long-Term Debt

Convertible Debt

14. Convertible Notes

On April 28, 2023, the Company closed on a new convertible debt facility which enables the Company to access up to $10,000,000 in aggregate principal amount of convertible notes (the “Convertible Notes”). The convertible facility has a term of three years, with an annual interest rate of 12.0%, comprised of 6.0% cash and 6.0% PIK. The initial tranche's principal amount of Convertible Notes outstanding in the amount of $2,000,000, plus all PIK and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to $0.145. For each future tranche advanced, the principal amount of Convertible Notes outstanding, plus all paid-in-kind interest and all other accrued but unpaid interest thereunder, is convertible into Subordinate Voting Shares of the Company at the option of the holders at any time by written notice to the Company, at a conversion price equal to the lesser of $0.145 or a 20.0% premium over the 30-day volume weighted average price of the Company’s Subordinate Voting Shares calculated on the day prior to the date on which each tranche is advanced, if permitted by the Canadian Securities Exchange. The lenders also have the right to advance any remaining undrawn funds on the convertible loan facility to the Company at any time. If the notes are not converted, the outstanding principal amount and unpaid PIK interest is due on April 30, 2026.

During the year ended December 31, 2023, the Company closed eight additional tranches of Convertible Notes, which are convertible into Subordinate Voting Shares at a conversion price of $0.145. Total proceeds received from these tranches amounted to $8,000,000.

In connection with this financing, the Company issued 6,250,000 warrants to purchase Subordinate Voting Shares of the Company to the lenders. These warrants have a five year term, a strike price of $0.145, and were valued at $497,055. The value of these warrants and other legal and administrative expenses amounting to $1,346,793 are treated as deferred financing costs. All deferred financing costs are treated as a contra-liability, to be netted against the outstanding loan balance and amortized over the remaining life of the loan. As of  March 31, 2024 $967,587 (December 31, 2023 - $1,083,697) of deferred financing costs remain unamortized.

The following table shows a summary of the Company’s convertible debt:

	March 31,		December 31,
	2024		2023
Beginning of year	$	9,140,257	$	—
Proceeds		—		10,000,000
Deferred financing costs		—		(1,346,793)
PIK interest		153,686		223,954
Amortization of deferred financing costs		116,110		263,096
End of year	$	9,410,053		9,140,257
Less: current portion		—		—
Total convertible debt	$	9,410,053	$	9,140,257

XML

Stockholders' Equity

3 Months Ended

Mar. 31, 2024

Stockholders' Equity

Stockholders' Equity

15. Stockholders’ Equity

Shares

The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of March 31, 2024. The liquidation and dividend rights are identical among shares equally in the Company’s earnings and losses on an as converted basis.

	Par Value	Authorized	Voting Rights
Subordinate Voting Share (“SVS”)	—	Unlimited	1 vote for each share
Multiple Voting Share (“MVS”)	—	Unlimited	100 votes for each share
Super Voting Share	—	Unlimited	1,000 votes for each share

Subordinate Voting Shares

Holders of Subordinate Voting Shares are entitled to one vote in respect of each Subordinate Voting Share held.

Multiple Voting Shares

Holders of Multiple Voting Shares are entitled to one hundred votes for each Multiple Voting Share held.

Multiple Voting Shares each have the restricted right to convert to one hundred Subordinate Voting Shares subject to adjustments for certain customary corporate changes.

Super Voting Shares

Holders of Super Voting Shares are entitled to one thousand votes per Super Voting Share. Each Super Voting share is convertible into one Multiple Voting Share.

Shares Issued

During the three months ended March 31, 2024, 10,342 Multiple Voting Shares were redeemed for 1,034,200 Subordinate Voting Shares.

XML

Stock-Based Compensation

3 Months Ended

Mar. 31, 2024

Stock-Based Compensation

Stock-Based Compensation

16. Stock-Based Compensation

Stock Options

In January 2019, the Company adopted the 2019 Equity Incentive Plan under which the Company may grant incentive stock option, restricted shares, restricted share units, or other awards. Under the terms of the plan, a total of ten percent of the number of shares outstanding assuming conversion of all super voting shares and multiple voting shares to subordinate voting shares are permitted to be issued. The exercise price for incentive stock options issued under the plan will be set by the committee but will not be less 100% of the fair market value of the Company’s shares on the date of grant. Incentive stock options have a maximum term of 10 years from the date of grant. The incentive stock options vest at the discretion of the Board of Directors.

Options granted under the equity incentive plan were valued using the Black-Scholes option pricing model with the following weighted average assumptions:

	March 31,		March 31,
	2024		2023
Risk-Free Interest Rate	N/A		3.84	%
Weighted Average Exercise Price	N/A	$	0.28
Weighted Average Stock Price	N/A	$	0.17
Expected Life of Options (years)	N/A		5.85
Expected Annualized Volatility	N/A	%	100.00	%
Grant Fair Value	N/A	$	0.13
Expected Forfeiture Rate	N/A		N/A
Expected Dividend Yield	N/A		N/A

Stock option activity for the three months ended March 31, 2024, and for the year ended December 31, 2023, is presented below:

		Weighted Average		Weighted Avg.
	Number of Options	Exercise Price		Remaining Life
Balance, December 31, 2022	23,547,558	$	0.66	7.30
Forfeitures	(4,137,079)		0.82	—
Granted	10,558,845		0.25	6.42
Balance, December 31, 2023	29,969,324	$	0.50	6.18
Forfeitures	(23,813)		1.19	—
Options Outstanding at March 31, 2024	29,945,511	$	0.50	5.93
Options Exercisable at March 31, 2024	24,596,552	$	0.42	5.53

During the three month periods ended March 31, 2024 and 2023, the Company recognized $86,732 and $1,399,258 in stock-based compensation relating to stock options, respectively. As of March 31, 2024, the total unrecognized compensation costs related to unvested stock options awards granted was $416,563. In addition, the weighted average period over which the unrecognized compensation expense is expected to be recognized is approximately 1.7 years. The total intrinsic value of stock options outstanding and exercisable as of March 31, 2024, was $3,388,310 and $2,973,949, respectively.

The Company does not estimate forfeiture rates when calculating compensation expense. The Company records forfeitures as they occur.

Warrants

Subordinate Voting Share (SVS) warrants entitle the holder to purchase one subordinate voting share of the Company. Multiple Voting Share (MVS) warrants entitle the holder to purchase one multiple voting share of the Company.

A summary of the warrants outstanding is as follows:

	Number of	Weighted Average		Weighted Average
SVS Warrants	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	150,000	$	1.49	2.00
Granted	16,250,000		0.20	5.00
Warrants outstanding at December 31, 2023	16,400,000	$	0.21	4.57
Granted	—		—	—
Warrants outstanding at March 31, 2024	16,400,000	$	0.21	4.32
Warrants exercisable at March 31, 2024	16,400,000	$	0.21	4.32

	Number of	Weighted Average		Weighted Average
SVS Warrants Denominated in C$	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	3,037,649	$	3.50	3.23
Granted	—		—	—
Warrants outstanding at December 31, 2023	3,037,649	$	3.50	2.23
Granted	—		—	—
Warrants outstanding at March 31, 2024	3,037,649	$	3.50	1.98
Warrants exercisable at March 31, 2024	3,037,649	$	3.50	1.98

During the three months ended March 31, 2024, and 2023, $0 in stock-based compensation expense was recorded in connection with outstanding warrants.

Restricted Stock Units (“RSUs”)

The expense associated with RSUs is based on the closing share price of the Company’s subordinate voting shares on the business day immediately preceding the grant date, adjusted for the absence of future dividends and is amortized on a straight-line basis over the periods during which the restrictions lapse. The Company currently has RSUs that vest over a three year period. The awards are generally subject to forfeiture in the event of termination of employment. During the three months ended March 31, 2024, the Company recognized $93,057 and $276,336, respectively, in stock-based compensation expense related to RSUs.

A summary of RSUs is as follows:

		Weighted Avg.
	Number of Shares	Fair Value
Balance, December 31, 2022	3,221,677	$	0.81
Forfeitures	(678,666)		0.54
Balance, December 31, 2023 and March 31, 2024	2,543,011		0.88
Vested at March 31, 2024	1,025,253	$	0.95

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2024

Commitments and Contingencies

Commitments and Contingencies

17. Commitments and Contingencies

Legal proceedings

Schneyer

On February 25, 2019, Dr. Mark Schneyer (“Schneyer”) filed a lawsuit in Minnesota District Court, Fourth District (the “Court”), on his own behalf and, derivatively, on behalf of Dorchester Capital, LLC, naming Vireo Health, Inc. (“Vireo U.S.”), Dorchester Management, LLC (“Dorchester Management”), and Dorchester Capital, LLC (“Capital”), as defendants. The essence of the claims made by Schneyer is Vireo U.S. paid an inadequate price for MaryMed, LLC (“MaryMed”), which it purchased it from Capital in 2018, and that the consideration given – shares of preferred stock in Vireo U.S. – was distributed inappropriately by Capital at the direction of Dorchester Management (the managing member of Capital). Schneyer, who is a Class B member of Capital, sought unspecified damages in excess of $50,000 and other relief. Dorchester Management, LLC is an affiliated entity to Vireo U.S. and was previously used as a management company over Dorchester Capital, LLC. It no longer has active operations following Vireo Health, Inc.’s acquisition of MaryMed, LLC in 2018. It is owned and controlled by Kyle E. Kingsley and Amber H. Shimpa, executive officers and directors of Vireo U.S. and the Company.

While Vireo U.S. continues to believe that Schneyer’s claims lack merit, it agreed to settle the litigation in April 2023 to avoid the expense, distraction and risk of the pre-trial and trial processes. Entering into this settlement in no way changed the defendants’ position that they did nothing wrong and that the claims were baseless.

Verano

On January 31, 2022, the Company entered into the Arrangement Agreement with Verano, pursuant to which Verano was to acquire all of the issued and outstanding shares of Goodness Growth pursuant to a Plan of Arrangement. Subject to the terms and conditions set forth in the Arrangement Agreement and the Plan of Arrangement, holders of Goodness Growth Shares would receive 0.22652 of a Verano Subordinate Voting Share, subject to adjustment as described below, for each Subordinate Voting Share held, and 22.652 Verano Subordinate Voting Shares for each Multiple Voting Share and Super Voting Share held, immediately prior to the effective time of the Arrangement.

On October 13, 2022, Goodness Growth received a notice of purported termination of the Arrangement Agreement (the “Notice”) from Verano. The Notice asserted certain breaches of the Arrangement Agreement, including claims the Company’s public filings and communications with respect to its business and ongoing operations were misleading and that the Company breached its representations to Verano under the Arrangement Agreement. Verano also claimed, as a result of such breaches, it is entitled to payment of a $14,875,000 termination fee and its transaction expenses. Goodness Growth denies all of Verano’s allegations and affirmatively asserts that it has complied with its obligations under the Arrangement Agreement, and with its disclosure obligations under US and Canadian law, in all material respects at all times. The Company believes that Verano has no factual or legal basis to justify or support its purported termination of the Arrangement Agreement, which the Company determined to treat as a repudiation of the Arrangement Agreement.

On October 21, 2022, Goodness Growth commenced an action in the Supreme Court of British Columbia against Verano after Verano wrongfully repudiated the Arrangement Agreement. The Company is seeking damages, costs and interest, based on Verano's breach of contract and of its duty of good faith and honest performance.

On November 14, 2022, Verano filed counterclaims against the Company for the termination fee and transaction expenses described above.

On July 31, 2023, the Company filed a requisition for adjournment of its application filed July 14, 2023, and set for hearing on July 31, 2023 to compel Verano’s compliance with document production based upon the Company’s belief that Verano was engaging in tactics to delay the litigation. 

Throughout 2023, the Company served 4 lists of documents, reviewed document production from Verano, and prepared for examinations for discovery.  The Company also prepared materials in anticipation of seeking summary determination of its claim, which it anticipates filing within 30 days.

Due to uncertainties inherent in litigation, it is not possible for Goodness Growth to predict the timing or final outcome of the legal proceedings against Verano or to determine the amount of damages, if any, that may be awarded.  The damages sought will be significant and material given that Verano’s breach left the Company in a vulnerable position resulting in the Company being constrained in its ability to fund growth initiatives that were desirable and that its competitors were able to undertake, most notably in Minnesota and New York markets.

Lease commitments

The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2041.

XML

Selling, General and Administrative Expenses

3 Months Ended

Mar. 31, 2024

Selling, General and Administrative Expenses

Selling, General and Administrative Expenses

18. Selling, General and Administrative Expenses

Selling, general and administrative expenses are comprised of the following items:

	Three Months Ended March 31,
	2024		2023
Salaries and benefits	$	3,512,736	$	3,797,410
Professional fees		1,427,096		890,167
Insurance expenses		569,185		635,439
Marketing		222,014		225,113
Other expenses		1,320,582		1,608,706
Total	$	7,051,613	$	7,156,835

XML

Other Income (Expense)

3 Months Ended

Mar. 31, 2024

Other Income (Expense)

Other Income (Expense)

19. Other Income (Expense)

On May 25, 2023, the Company and Grown Rogue International, Inc. (“Grown Rogue”) entered into a strategic agreement whereby Grown Rogue will support Goodness Growth in the optimization of its cannabis flower products. As part of this strategic agreement Grown Rogue granted the Company 8,500,000 warrants to purchase subordinate voting shares of Grown Rogue on October 5, 2023. These warrants were valued at $3,265,231 on March 31, 2024 using a stock price of $0.45, an exercise price of $0.17, an expected life of 4.52 years, an annual risk free rate of 4.21%, and volatility of 100%. The change in fair value relative to December 31, 2023 of $1,327,879 was recorded as other income in the unaudited condensed consolidated statement of loss and comprehensive loss for the three months ended March 31, 2024.

XML

Supplemental Cash Flow Information

3 Months Ended

Mar. 31, 2024

Supplemental Cash Flow Information

Supplemental Cash Flow Information

20. Supplemental Cash Flow Information⁽¹⁾

	March 31,		March 31,
	2024		2023
Cash paid for interest	$	6,799,193	$	5,731,120
Cash paid for income taxes		—		—
Change in construction accrued expenses		(121,433)		—
Warrants issued in connection with financing activities		—		—

(1) For supplemental cash flow information related to leases, refer to Note 9.

XML

Financial Instruments

3 Months Ended

Mar. 31, 2024

Financial Instruments

Financial Instruments

21. Financial Instruments

Credit risk

Credit risk is the risk of loss associated with counterparty’s inability to fulfill its payment obligations. The Company’s credit risk is primarily attributable to cash, accounts receivable, and notes receivable. A small portion of cash is held on hand, from which management believes the risk of loss is remote. Receivables relate primarily to wholesale sales. The Company does not have significant credit risk with respect to customers. The Company’s maximum credit risk exposure is equivalent to the carrying value of these instruments. The Company has been granted licenses pursuant to the laws of the states of Maryland, Minnesota, and New York with respect to cultivating, processing, and/or distributing marijuana. Presently, this industry is illegal under United States federal law. The Company has adhered, and intends to continue to adhere, strictly to the applicable state statutes in its operations.

Liquidity risk

The Company’s approach to managing liquidity risk is to ensure that it will have sufficient liquidity to meet liabilities when due. As of March 31, 2024, the Company’s financial liabilities consist of accounts payable, accrued liabilities, debt,

and convertible debt. The Company manages liquidity risk by reviewing its capital requirements on an ongoing basis. Historically, the Company’s main source of funding has been additional funding from investors and debt issuances. The Company’s access to financing is always uncertain. There can be no assurance of continued access to significant equity or debt financing.

Legal Risk

Goodness Growth operates in the United States. The U.S. federal government regulates drugs through the Controlled Substances Act (21 U.S.C. § 811), which places controlled substances, including cannabis, in a schedule. Cannabis is classified as a Schedule I drug. Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the U.S., and a lack of accepted safety for the use of the drug under medical supervision. The U.S. Food and Drug Administration has not approved marijuana as a safe and effective drug for any indication. In the U.S. marijuana is largely regulated at the state level. State laws regulating cannabis are in direct conflict with the federal Controlled Substances Act, which makes cannabis use and possession federally illegal.

Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument will fluctuate because of changes in foreign currency rates. Given the Company’s financial transactions are rarely denominated in a foreign currency, there is minimal foreign currency risk exposure.

Interest rate risk

Interest rate risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market interest rates. The Company currently carries variable interest-bearing debt subject to fluctuations in the United States Prime rate. A change of 100 basis points in interest rates during the three months ended March 31, 2024, would have resulted in a corresponding change in the statement of loss and comprehensive loss of $138,570.

XML

Related Party Transactions

3 Months Ended

Mar. 31, 2024

Related Party Transactions

Related Party Transactions

22. Related Party Transactions

As of March 31, 2024, and December 31, 2023, there were $0 and $121,846 due to related parties, respectively.

XML

Subsequent Events

3 Months Ended

Mar. 31, 2024

Subsequent Events

Subsequent Events

23. Subsequent Events

On April 1, 2024, the Company executed a eighth amendment to its lease with its landlord on its cannabis cultivation and manufacturing facilities located in Johnstown, New York. As part of the eighth amendment to the lease in Johnstown, the Company extended its option to terminate the lease. Written notice of termination now needs to be provided by June 15, 2024. Additionally, the Company has a purchase option to buy the premises for $81,000,000. The purchase option extends through March 27, 2026, and the purchase price increases 3% every six months.

On April 1, 2024, ACE Ventures, LLC (“Ace”), a minority-owned business partnership in the State of New York, and the Company executed a binding term sheet whereby Ace plans to acquire the Company’s subsidiary, Vireo Health of New York (“VireoNY”), pending the satisfaction of closing conditions, including secured capital commitments and regulatory approval. Terms of the transaction include a purchase price between $3.0 and $5.0 million for Vireo Health of New York’s licenses, inventory and assets, as well as either Ace’s assumption of the lease agreement with Innovative Industrial Properties (“IIP”) for the Johnstown, NY cannabis cultivation and manufacturing campus or Ace’s acquisition of this campus. Ace has agreed to take financial responsibility for VireoNY’s operations, including its operating losses, beginning on April 1, 2024. These activities are expected to be supported initially by a $2.5 million unsecured loan from the Company to VireoNY.

On May 1, 2024, The Company announced that Josh Rosen, who has served as Interim CEO since February of 2023, has been appointed as Chief Executive Officer, effective immediately. Mr. Rosen, retains his Interim Chief Financial Officer title.

On May 1, 2024, The Company announced that it is in ongoing discussions with its senior secured lender, Chicago Atlantic Admin, LLC, an affiliate of Green Ivy Capital, to finalize a longer-term extension of its credit agreement. While this process remains ongoing, the parties have agreed to a short-term extension of the maturity date on their term loan until June 14, 2024, matching all other terms of the existing agreement.

On May 2, 2024, the Company announced that it has filed an application with the Supreme Court of British Columbia for summary determination in its ongoing litigation with Verano Holdings, Inc. (“Verano”) related to Verano’s wrongful termination of the share exchange agreement (the “Arrangement Agreement”) between the parties pursuant to which Verano agreed to acquire all of the outstanding capital stock of the Company in a transaction announced on February 1, 2022. The Company is seeking substantial damages, specifically US $869.0 million, as well as other costs and legal fees, based on Verano’s breach of contract and of its duty of good faith and honest performance. While the Company’s filing of its application for summary determination reflects its belief that Verano’s defense against its claims of unlawful conduct is without merit, the Company can make no assurances regarding the expected timeframe to resolve this litigation, or its ability to recover damages from Verano.

XML

Summary of Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2024

Summary of Significant Accounting Policies

Basis of presentation

Basis of presentation

The accompanying unaudited condensed consolidated financial statements reflect the accounts of the Company. The information included in these statements should be read in conjunction with the Annual Financial Statements. The unaudited condensed consolidated financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”) and pursuant to the rules and regulations of the SEC. In the opinion of management, the financial data presented includes all adjustments necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented. Results of interim periods should not be considered indicative of the results for the full year. These unaudited interim condensed consolidated financial statements include estimates and assumptions of management that affect the amounts reported in the unaudited condensed consolidated financial statements. Actual results could differ from these estimates.

Basis of consolidation

Basis of consolidation

These unaudited condensed consolidated financial statements include the accounts of the following entities wholly owned, or effectively controlled by the Company during the period ended March 31, 2024:

Name of entity	Place of  incorporation
Vireo Health, Inc.	Delaware, USA
Vireo Health of New York, LLC	New York, USA
Minnesota Medical Solutions, LLC	Minnesota, USA
MaryMed, LLC	Maryland, USA
Vireo of Charm City, LLC	Maryland, USA
Vireo Health of Massachusetts, LLC	Delaware, USA
Mayflower Botanicals, Inc.	Massachusetts, USA
Resurgent Biosciences, Inc.	Delaware, USA
Vireo Health of Puerto Rico, LLC	Delaware, USA
Vireo Health de Puerto Rico, Inc.	Puerto Rico
XAAS Agro, Inc.	Puerto Rico
Vireo Health of Nevada 1, LLC	Nevada, USA
Verdant Grove, Inc.	Massachusetts, USA

The entities listed are wholly owned or effectively controlled by the Company and have been formed or acquired to support the intended operations of the Company, and all intercompany transactions and balances have been eliminated in the Company's unaudited condensed consolidated financial statements. Red Barn Growers, Inc. and all New Mexico assets and liabilities were divested in June of 2023.

Recently adopted accounting pronouncements and New accounting pronouncements not yet adopted

Recently adopted accounting pronouncements

None.

New accounting pronouncements not yet adopted

ASU 2023-07 In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update ("ASU") 2023-07, Improvements to Reportable Segment Disclosures (Topic 280). This ASU updates reportable segment disclosure requirements by requiring disclosures of significant reportable segment expenses that are regularly provided to the Chief Operating Decision Maker (“CODM”) and included within each reported measure of a segment's profit or loss. This ASU also requires disclosure of the title and position of the individual identified as the CODM and an explanation of how the CODM uses the reported measures of a segment’s profit or loss in assessing segment performance and deciding how to allocate resources. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company has not adopted the standard for the interim periods presented herein, but will adopt the standard on or before December 31, 2024. This ASU will result in additional required disclosures when adopted, where applicable.

ASU 2023-09 In December 2023, the FASB issued ASU 2023-09, Improvements to Income Tax Disclosures (Topic 740). The ASU requires disaggregated information about a reporting entity’s effective tax rate reconciliation as well as additional information on income taxes paid. The ASU is effective on a prospective basis for annual periods beginning after December 15, 2024. Early adoption is also permitted for annual financial statements that have not yet been issued or made available for issuance. Once adopted, this ASU will result in additional disclosures.

Net loss per share

Net loss per share

Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company during the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential dilutive common share equivalents consist of stock options, warrants, and restricted stock units.

In computing diluted earnings per share, common share equivalents are not considered in periods in which a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. The Company recorded a net loss for the three month periods ended March 31, 2024, and 2023, presented in these financial statements, and as such there is no difference between the Company’s basic and diluted net loss per share for these periods.

The anti-dilutive shares outstanding for the three month period ending March 31, 2024, and 2023 were as follows:

	March 31,
	2024	2023
Stock options	29,945,511	28,566,282
Warrants	19,437,649	3,187,649
RSUs	2,543,011	3,102,765
Convertible debt	71,569,927	—
Total	123,496,098	34,856,696

Revenue Recognition

Revenue Recognition

The Company’s primary source of revenue is from wholesale of cannabis products to dispensary locations and direct retail sales to eligible customers at the Company-owned dispensaries. Substantially all of the Company’s retail revenue is from the direct sale of cannabis products to adult-use and medical customers.

The following table represents the Company’s disaggregated revenue by source:

	Three Months Ended March 31,
	2024		2023
Retail	$	19,599,440	$	16,471,799
Wholesale		4,487,875		2,616,624
Total	$	24,087,315	$	19,088,423

XML

Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2024

Summary of Significant Accounting Policies

Schedule of entities wholly owned, or effectively controlled by Company

Name of entity	Place of  incorporation
Vireo Health, Inc.	Delaware, USA
Vireo Health of New York, LLC	New York, USA
Minnesota Medical Solutions, LLC	Minnesota, USA
MaryMed, LLC	Maryland, USA
Vireo of Charm City, LLC	Maryland, USA
Vireo Health of Massachusetts, LLC	Delaware, USA
Mayflower Botanicals, Inc.	Massachusetts, USA
Resurgent Biosciences, Inc.	Delaware, USA
Vireo Health of Puerto Rico, LLC	Delaware, USA
Vireo Health de Puerto Rico, Inc.	Puerto Rico
XAAS Agro, Inc.	Puerto Rico
Vireo Health of Nevada 1, LLC	Nevada, USA
Verdant Grove, Inc.	Massachusetts, USA

Schedule of anti-dilutive shares outstanding

	March 31,
	2024	2023
Stock options	29,945,511	28,566,282
Warrants	19,437,649	3,187,649
RSUs	2,543,011	3,102,765
Convertible debt	71,569,927	—
Total	123,496,098	34,856,696

Schedule of disaggregated revenue

	Three Months Ended March 31,
	2024		2023
Retail	$	19,599,440	$	16,471,799
Wholesale		4,487,875		2,616,624
Total	$	24,087,315	$	19,088,423

XML

Business Combinations and Dispositions (Tables)

3 Months Ended

Mar. 31, 2024

Business Combinations and Dispositions

Schedule of assets and liabilities held for sale

Assets held for sale	March 31,		December 31,
	2024		2023
Property and equipment	$	87,333,100	$	86,864,965
Intangible assets		662,500		662,500
Operating lease, right-of-use asset		3,381,612		3,381,612
Deposits		920,233		304,194
Total assets held for sale	$	92,297,445	$	91,213,271
Liabilities held for sale
Right of Use Liability	$	88,373,080	$	88,326,323
Total liabilities held for sale	$	88,373,080	$	88,326,323

XML

Accounts Receivable (Tables)

3 Months Ended

Mar. 31, 2024

Accounts Receivable

Schedule of accounts receivables

	March 31,		December 31,
	2024		2023
Trade receivable	$	1,862,555	$	2,256,763
Tax withholding receivable		174,660		174,660
Other		716,458		655,217
Total	$	2,753,673	$	3,086,640

XML

Inventory (Tables)

3 Months Ended

Mar. 31, 2024

Inventory

Schedule of inventory

	March 31,		December 31,
	2024		2023
Work-in-progress	$	13,154,921	$	13,058,348
Finished goods		5,318,269		5,278,331
Other		884,060		949,191
Total	$	19,357,250	$	19,285,870

Schedule of inventory valuation adjustments

	March 31,
	2024		2023
Work-in-progress	$	(188,200)	$	15,072
Finished goods		(115,800)		(25,072)
Total	$	(304,000)	$	(10,000)

XML

Prepayments and other current assets (Tables)

3 Months Ended

Mar. 31, 2024

Prepayments and other current assets

Schedule of prepayments and other current assets

	March 31,		December 31,
	2024		2023
Prepaid Insurance	$	641,365	$	806,610
Other Prepaid Expenses		404,762		529,624
Total	$	1,046,127	$	1,336,234

XML

Property and Equipment, Net (Tables)

3 Months Ended

Mar. 31, 2024

Property and Equipment, Net

Schedule of property and equipment, net

	March 31,		December 31,
	2024		2023
Land	$	863,105	$	863,105
Buildings and leasehold improvements		15,204,145		15,124,915
Furniture and equipment		7,035,631		7,807,250
Software		39,388		242,204
Vehicles		271,769		284,000
Construction-in-progress		986,391		128,220
Right of use asset under finance lease		7,938,138		7,938,138
		32,338,567		32,387,832
Less: accumulated depreciation		(8,797,122)		(9,096,649)
Total	$	23,541,445	$	23,291,183

XML

Leases (Tables)

3 Months Ended

Mar. 31, 2024

Leases

Schedule of components of lease expenses

	March 31,		March 31,
	2024		2023
Finance lease cost
Amortization of ROU assets	$	143,441	$	270,935
Interest on lease liabilities		3,544,177		2,725,966
Operating lease costs		432,444		590,920
Total lease costs	$	4,120,062	$	3,587,821

Schedule of Future minimum lease payments of operating leases

	Operating Leases		Finance Leases
	March 31, 2024		March 31, 2024		Total
2024	$	1,673,583	$	10,183,227	$	11,856,810
2025		3,047,603		13,773,155		16,820,758
2026		2,727,346		14,183,661		16,911,007
2027		2,474,144		14,606,527		17,080,671
2028		2,254,049		15,042,128		17,296,177
Thereafter		7,824,515		218,572,918		226,397,433
Total minimum lease payments	$	20,001,240	$	286,361,616	$	306,362,856
Less discount to net present value		(4,750,354)		(192,721,556)		(197,471,910)
Less liabilities held for sale		(3,096,598)		(85,276,482)		(88,373,080)
Present value of lease liability	$	12,154,288	$	8,363,578	$	20,517,866

Schedule of Future minimum lease payments of financing leases

	Operating Leases		Finance Leases
	March 31, 2024		March 31, 2024		Total
2024	$	1,673,583	$	10,183,227	$	11,856,810
2025		3,047,603		13,773,155		16,820,758
2026		2,727,346		14,183,661		16,911,007
2027		2,474,144		14,606,527		17,080,671
2028		2,254,049		15,042,128		17,296,177
Thereafter		7,824,515		218,572,918		226,397,433
Total minimum lease payments	$	20,001,240	$	286,361,616	$	306,362,856
Less discount to net present value		(4,750,354)		(192,721,556)		(197,471,910)
Less liabilities held for sale		(3,096,598)		(85,276,482)		(88,373,080)
Present value of lease liability	$	12,154,288	$	8,363,578	$	20,517,866

Schedule of supplemental cash flow information

	March 31,
	2024		2023
Cash paid for amounts included in the measurement of lease liabilities:
Lease principal payments - finance	$	71,066	$	288,574
Lease principal payments - operating		168,554		—
Non-cash additions to ROU assets		9,270,915		4,054,328
Amortization of operating leases		170,196		309,747

Schedule of other information about leases

	March 31,
	2024		2023
Weighted-average remaining lease term (years) – operating leases	8.08		4.67
Weighted-average remaining lease term (years) – finance leases	16.82		17.57
Weighted-average discount rate – operating leases	8.58	%	15.00	%
Weighted-average discount rate – finance leases	16.21	%	15.33	%

XML

Goodwill (Tables)

3 Months Ended

Mar. 31, 2024

Goodwill

Schedule of change in carrying amount of goodwill

Goodwill - December 31, 2022	$	183,836
Divestitures (Note 3)		(183,836)
Goodwill - December 31, 2023 and March 31, 2024	$	—

XML

Intangibles (Tables)

3 Months Ended

Mar. 31, 2024

Intangibles

Schedule of intangible assets

	Licenses & Trademarks
Balance, December 31, 2022	$	8,776,946
Divestitures		(409,239)
Additions		1,090,919
Amortization		(728,419)
Write off		(11,630)
Balance, December 31, 2023	$	8,718,577
Amortization		(204,812)
Balance, March 31, 2024	$	8,513,765

XML

Accounts Payable and Accrued Liabilities (Tables)

3 Months Ended

Mar. 31, 2024

Accounts Payable and Accrued Liabilities

Schedule of accounts payable and accrued liabilities

	March 31,		December 31,
	2024		2023
Accounts payable – trade	$	2,111,125	$	1,769,346
Accrued Expenses		4,626,887		4,852,648
Taxes payable		346,450		218,563
Contract liability		885,696		833,832
Total accounts payable and accrued liabilities	$	7,970,158	$	7,674,389

XML

Long-Term Debt (Tables)

3 Months Ended

Mar. 31, 2024

Long-Term Debt

Schedule of long-term debt

	March 31,		December 31,
	2024		2023
Beginning of year	$	60,220,535	$	58,028,604
Principal repayments		(1,050,000)		(2,976,362)
Deferred financing costs		—		(1,407,903)
PIK interest		1,323,516		1,607,032
Amortization of deferred financing costs		402,237		4,969,164
End of period		60,896,288		60,220,535
Less: current portion		60,896,288		60,220,535
Total long-term debt	$	—	$	—

Schedule of stated maturities of long-term debt

2024	$	60,896,288
Total	$	60,896,288

XML

Convertible Debt (Tables)

3 Months Ended

Mar. 31, 2024

Long-Term Debt

Schedule of convertible debt

	March 31,		December 31,
	2024		2023
Beginning of year	$	9,140,257	$	—
Proceeds		—		10,000,000
Deferred financing costs		—		(1,346,793)
PIK interest		153,686		223,954
Amortization of deferred financing costs		116,110		263,096
End of year	$	9,410,053		9,140,257
Less: current portion		—		—
Total convertible debt	$	9,410,053	$	9,140,257

XML

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2024

Stockholders' Equity

Schedule of shares by class

	Par Value	Authorized	Voting Rights
Subordinate Voting Share (“SVS”)	—	Unlimited	1 vote for each share
Multiple Voting Share (“MVS”)	—	Unlimited	100 votes for each share
Super Voting Share	—	Unlimited	1,000 votes for each share

XML

Stock-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2024

Stock-Based Compensation

Schedule of weighted average valuation assumptions for stock options

	March 31,		March 31,
	2024		2023
Risk-Free Interest Rate	N/A		3.84	%
Weighted Average Exercise Price	N/A	$	0.28
Weighted Average Stock Price	N/A	$	0.17
Expected Life of Options (years)	N/A		5.85
Expected Annualized Volatility	N/A	%	100.00	%
Grant Fair Value	N/A	$	0.13
Expected Forfeiture Rate	N/A		N/A
Expected Dividend Yield	N/A		N/A

Schedule of stock option activity

		Weighted Average		Weighted Avg.
	Number of Options	Exercise Price		Remaining Life
Balance, December 31, 2022	23,547,558	$	0.66	7.30
Forfeitures	(4,137,079)		0.82	—
Granted	10,558,845		0.25	6.42
Balance, December 31, 2023	29,969,324	$	0.50	6.18
Forfeitures	(23,813)		1.19	—
Options Outstanding at March 31, 2024	29,945,511	$	0.50	5.93
Options Exercisable at March 31, 2024	24,596,552	$	0.42	5.53

Summary of warrants outstanding

	Number of	Weighted Average		Weighted Average
SVS Warrants	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	150,000	$	1.49	2.00
Granted	16,250,000		0.20	5.00
Warrants outstanding at December 31, 2023	16,400,000	$	0.21	4.57
Granted	—		—	—
Warrants outstanding at March 31, 2024	16,400,000	$	0.21	4.32
Warrants exercisable at March 31, 2024	16,400,000	$	0.21	4.32

	Number of	Weighted Average		Weighted Average
SVS Warrants Denominated in C$	Warrants	Exercise Price		Remaining Life
Warrants outstanding at December 31, 2022	3,037,649	$	3.50	3.23
Granted	—		—	—
Warrants outstanding at December 31, 2023	3,037,649	$	3.50	2.23
Granted	—		—	—
Warrants outstanding at March 31, 2024	3,037,649	$	3.50	1.98
Warrants exercisable at March 31, 2024	3,037,649	$	3.50	1.98

Summary of RSU activity

		Weighted Avg.
	Number of Shares	Fair Value
Balance, December 31, 2022	3,221,677	$	0.81
Forfeitures	(678,666)		0.54
Balance, December 31, 2023 and March 31, 2024	2,543,011		0.88
Vested at March 31, 2024	1,025,253	$	0.95

XML

Selling, General and Administrative Expenses (Tables)

3 Months Ended

Mar. 31, 2024

Selling, General and Administrative Expenses

Schedule of selling, general and administrative expenses

	Three Months Ended March 31,
	2024		2023
Salaries and benefits	$	3,512,736	$	3,797,410
Professional fees		1,427,096		890,167
Insurance expenses		569,185		635,439
Marketing		222,014		225,113
Other expenses		1,320,582		1,608,706
Total	$	7,051,613	$	7,156,835

XML

Supplemental Cash Flow Information (Tables)

3 Months Ended

Mar. 31, 2024

Supplemental Cash Flow Information

Schedule of supplemental cash flow information

	March 31,		March 31,
	2024		2023
Cash paid for interest	$	6,799,193	$	5,731,120
Cash paid for income taxes		—		—
Change in construction accrued expenses		(121,433)		—
Warrants issued in connection with financing activities		—		—

(1) For supplemental cash flow information related to leases, refer to Note 9.

XML

Description of Business and Summary (Details) - Arrangement Agreement with Verano Holdings Corp		3 Months Ended	12 Months Ended
	Oct. 13, 2022 USD ($)	Mar. 31, 2024 item	Dec. 31, 2023 item	Jan. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Damages sought | $	$ 14,875,000
Lists of documents served for examination | item		4	4
Subordinate Voting Shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exchange ratio				0.22652
Multiple Voting Shares
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exchange ratio				22.652

XML

Summary of Significant Accounting Policies - Anti-dilutive shares outstanding (Details) - shares	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares outstanding	123,496,098	34,856,696
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares outstanding	29,945,511	28,566,282
Warrants
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares outstanding	19,437,649	3,187,649
RSUs
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares outstanding	2,543,011	3,102,765
Convertible debt
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive shares outstanding	71,569,927

XML

Summary of Significant Accounting Policies - Disaggregation of revenue (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Disaggregation of Revenue [Line Items]
Revenue	$ 24,087,315	$ 19,088,423
Retail
Disaggregation of Revenue [Line Items]
Revenue	19,599,440	16,471,799
Wholesale
Disaggregation of Revenue [Line Items]
Revenue	$ 4,487,875	$ 2,616,624

XML

Business Combinations and Dispositions - Assets Held for Sale (Details) - Disposal Group, Held-for-Sale, Not Discontinued Operations - USD ($)	3 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Disposal of Impairment loss	$ 0
Businesses In New York, Nevada and Massachusetts
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Operating losses	3,698,934
Assets held for sale
Property and equipment	87,333,100	$ 86,864,965
Intangible assets	662,500	662,500
Operating lease, right-of-use-asset	3,381,612	3,381,612
Deposits	920,233	304,194
Total assets held for sale	92,297,445	91,213,271
Liabilities held for sale
Right of Use Liability	88,373,080	88,326,323
Total liabilities held for sale	$ 88,373,080	$ 88,326,323

XML

Fair Value Measurements - Summary of assets that are measured at fair value on a recurring basis (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Fair Value Measurements
Asset impairment charge	$ 0

XML

Accounts Receivable (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounts Receivable
Trade receivable	$ 1,862,555	$ 2,256,763
Tax withholding receivable	174,660	174,660
Other	716,458	655,217
Total	2,753,673	3,086,640
Trade receivables, credit losses	46,619	95,686
Tax withholding receivable, credit losses	$ 159,275	$ 159,275

XML

Inventory (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Inventory
Work-in-progress	$ 13,154,921	$ 13,058,348
Finished goods	5,318,269	5,278,331
Other	884,060	949,191
Total	$ 19,357,250	$ 19,285,870

XML

Inventory - Schedule of inventory valuation adjustments (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Inventory
Work-in-progress	$ (188,200)	$ 15,072
Finished goods	(115,800)	(25,072)
Total	$ (304,000)	$ (10,000)

XML

Prepayments and other current assets (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Prepayments and other current assets
Prepaid Insurance	$ 641,365	$ 806,610
Other Prepaid Expenses	404,762	529,624
Total	$ 1,046,127	$ 1,336,234

XML

Property and Equipment, Net (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Property and Equipment, Net
Property and equipment, gross	$ 32,338,567		$ 32,387,832
Less: accumulated depreciation	(8,797,122)		(9,096,649)
Total	23,541,445		23,291,183
Property, Plant and Equipment, Net, by Type [Abstract]
Asset impairment charge	0
Property and Equipment net
Property, Plant and Equipment, Net, by Type [Abstract]
Asset impairment charge	0	$ 0
Land
Property and Equipment, Net
Property and equipment, gross	863,105		863,105
Buildings and leasehold improvements
Property and Equipment, Net
Property and equipment, gross	15,204,145		15,124,915
Furniture and equipment
Property and Equipment, Net
Property and equipment, gross	7,035,631		7,807,250
Software
Property and Equipment, Net
Property and equipment, gross	39,388		242,204
Vehicles
Property and Equipment, Net
Property and equipment, gross	271,769		284,000
Construction-in-progress
Property and Equipment, Net
Property and equipment, gross	986,391		128,220
Right of use asset under finance lease
Property and Equipment, Net
Property and equipment, gross	$ 7,938,138		$ 7,938,138

XML

Property and Equipment, Net - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Property, Plant and Equipment [Line Items]
Depreciation on property and equipment	$ 633,728	$ 893,598
Accumulated amortization of right of use asset under finance lease	2,507,998	1,934,235
Right of use asset under finance lease	7,938,138
Capitalized inventory	560,180	734,087
Asset impairment charge	0
Property and Equipment net
Property, Plant and Equipment [Line Items]
Asset impairment charge	$ 0	$ 0

XML

Leases - Components of lease expenses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases
Amortization of ROU assets	$ 143,441	$ 270,935
Interest on lease liabilities	3,544,177	2,725,966
Operating lease costs	432,444	590,920
Total lease costs	$ 4,120,062	$ 3,587,821

XML

Leases - Future minimum lease payments (Details)	Mar. 31, 2024 USD ($)
Operating Leases
2024	$ 1,673,583
2025	3,047,603
2026	2,727,346
2027	2,474,144
2028	2,254,049
Thereafter	7,824,515
Total minimum lease payments	20,001,240
Less discount to net present value	(4,750,354)
Less liabilities held for sale	(3,096,598)
Present value of lease liability	12,154,288
Finance Leases
2024	10,183,227
2025	13,773,155
2026	14,183,661
2027	14,606,527
2028	15,042,128
Thereafter	218,572,918
Total minimum lease payments	286,361,616
Less discount to net present value	(192,721,556)
Less liabilities held for sale	(85,276,482)
Present value of lease liability	8,363,578
Total
2024	11,856,810
2025	16,820,758
2026	16,911,007
2027	17,080,671
2028	17,296,177
Thereafter	226,397,433
Total minimum lease payments	306,362,856
Less discount to net present value	(197,471,910)
Less liabilities held for sale	(88,373,080)
Present value of lease liability	$ 20,517,866

XML

Leases - Narrative (Details) - USD ($)	Feb. 24, 2023	Feb. 22, 2024
Cannabis cultivation and manufacturing facilities located in Elk River, Minnesota
Leases
Allowance of tenant improvement		$ 2,000,000
Monthly base rent		82,500
Initial purchase price, amount		$ 13,000,000
Initial purchase price, percentage		3.00%
Fourth Amendment
Leases
Allowance of tenant improvement	$ 4,000,000
Amount of increase in monthly base rent	$ 50,000

XML

Leases - Supplemental cash flow information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Leases
Lease principal payments - finance	$ 71,066	$ 288,574
Lease principal payments - operating	168,554
Non-cash additions to ROU assets	9,270,915	4,054,328
Amortization of operating leases	$ 170,196	$ 309,747

XML

Leases - Other information (Details)	Mar. 31, 2024	Mar. 31, 2023
Leases
Weighted-average remaining lease term (years) - operating leases	8 years 29 days	4 years 8 months 1 day
Weighted-average remaining lease term (years) - finance leases	16 years 9 months 25 days	17 years 6 months 25 days
Weighted-average discount rate - operating leases	8.58%	15.00%
Weighted-average discount rate - finance leases	16.21%	15.33%

XML

Goodwill (Details)	15 Months Ended
	Mar. 31, 2024 USD ($)
Goodwill
Goodwill - December 31, 2022	$ 183,836
Divestitures (Note 3)	(183,836)
Goodwill - December 31, 2023 and March 31, 2024	$ 0

XML

Intangibles - Finite and Indefinite (Details) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Finite-lived intangible assets
Amortization	$ (180,034)	$ (159,766)
Amortization	(204,812)
Impairment, Intangible Asset, Finite-Lived, Statement of Income or Comprehensive Income [Extensible Enumeration]			Operating Expenses
Indefinite-lived intangible assets
Amortization	(180,034)	(159,766)
Amortization	(204,812)
Intangible assets
Beginning balance	8,718,577
Ending balance	8,513,765		$ 8,718,577
Licenses & Trademarks
Finite-lived intangible assets
Beginning balance	8,718,577	$ 8,776,946	8,776,946
Divestitures			(409,239)
Additions			1,090,919
Amortization			(728,419)
Amortization	(204,812)
Write off			(11,630)
Ending balance	8,513,765		8,718,577
Indefinite-lived intangible assets
Additions			1,090,919
Amortization			$ (728,419)
Amortization	$ (204,812)

XML

Intangibles - Expected Amortization (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Intangibles
Amortization	$ 204,812
Amortization of intangible assets	180,034	$ 159,766
Future minimum lease payments (principal and interest) on the leases
2024	819,655
2025	819,655
2026	819,655
2027	819,655
2028	$ 819,655

XML

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Accounts Payable and Accrued Liabilities
Accounts payable - trade	$ 2,111,125	$ 1,769,346
Accrued Expenses	4,626,887	4,852,648
Taxes payable	346,450	218,563
Contract liability	885,696	833,832
Total accounts payable and accrued liabilities	$ 7,970,158	$ 7,674,389

XML

Long-Term Debt - Narrative (Details) - USD ($)						3 Months Ended		12 Months Ended
	Nov. 19, 2023	Mar. 31, 2023	Jan. 31, 2022	Nov. 18, 2021	Mar. 25, 2021	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2017	Jan. 31, 2024	Dec. 31, 2023	Nov. 19, 2021	Dec. 31, 2019
Long-Term Debt
Note balance						$ 60,896,288				$ 60,220,535
Long-term debt
Long-Term Debt
Deferred financing costs as contra liability									$ 201,015	$ 1,524,531
Subordinate Voting Shares
Long-Term Debt
Shares issued in private placement (in shares)		15,000,000
Promissory Note
Long-Term Debt
Note payable amount								$ 1,010,000				$ 1,110,000
Interest rate								15.00%
Frequency of periodic payments								monthly
Promissory Note | Charm City Medicus, LLC
Long-Term Debt
Note payable amount											$ 2,000,000
Interest rate	15.00%										8.00%
Principal amount paid off	$ 1,000,000
Note balance	$ 1,000,000
Maturity date	Nov. 19, 2024
Credit Facility
Long-Term Debt
Interest rate				15.00%
Maximum aggregate principal amount				$ 4,200,000	$ 46,000,000
Proceeds from Credit Facility					$ 26,000,000
Interest rate, paid in kind				2.00%	2.75%
Accrued deferred financing cost issued		15,000,000					15,000,000
Deferred financing costs fair value		$ 1,407,903
Price per share		$ 0.094					$ 0.094
Percentage of discount to market price		22.00%
Trading lock up period		4 months
Credit Facility | Interest expense
Long-Term Debt
Monthly credit monitoring fee						$ 130,400	$ 130,400
Credit Facility | Prime Rate
Long-Term Debt
Interest rate (variable rate)					10.375%
Credit Facility | Charm City Medicus, LLC
Long-Term Debt
Interest held as collateral	25.00%
Arrangement Agreement with Verano Holdings Corp
Long-Term Debt
Interest rate			13.375%
Interest rate, paid in kind			2.75%
Arrangement Agreement with Verano Holdings Corp | Maximum
Long-Term Debt
Maximum aggregate principal amount			$ 55,000,000
Arrangement Agreement with Verano Holdings Corp | Prime Rate
Long-Term Debt
Interest rate (variable rate)			10.375%

XML

Long-Term Debt - Summary (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Long-Term Debt
Less: current portion	$ 60,896,288	$ 60,220,535
Promissory Note And Line Of Credit
Long-Term Debt
Beginning of year	60,220,535	58,028,604
Principal repayments	(1,050,000)	(2,976,362)
Deferred financing costs		(1,407,903)
PIK interest	1,323,516	1,607,032
Amortization of deferred financing costs	402,237	4,969,164
End of period	60,896,288	60,220,535
Less: current portion	60,896,288	60,220,535
Stated maturities of long-term debt
2024	60,896,288
Total	$ 60,896,288	$ 60,220,535

XML

Convertible Debt (Details)		3 Months Ended	12 Months Ended
	Apr. 28, 2023 USD ($) $ / shares	Mar. 31, 2024 USD ($) $ / shares shares	Dec. 31, 2023 USD ($) tranche $ / shares
Convertible Debt
Exercise price of warrants (in dollars per share) | $ / shares		$ 0.17
Convertible Notes
Convertible Debt
Maximum aggregate principal amount	$ 10,000,000
Debt instrument, term	3 years
Interest rate	12.00%
Cash interest rate	6.00%
Interest rate, paid in kind	6.00%
Amount converted			$ 8,000,000
Conversion price per share | $ / shares		$ 0.145	$ 0.145
Number of additional tranches | tranche			8
Warrants issued | shares		6,250,000
Term of warrants		5 years
Warrants issued in financing activities		$ 497,055
Legal and administrative expenses		1,346,793
Deferred financing costs unamortized		$ 967,587	$ 1,083,697
Convertible Debt, Tranche 1
Convertible Debt
Amount converted	$ 2,000,000
Conversion price per share | $ / shares	$ 0.145
Convertible Debt, Tranches 2 and 3 | Maximum
Convertible Debt
Conversion price per share | $ / shares	$ 0.145
Conversion premium, as a percentage of share price	20.0

XML

Convertible Debt - Summary (Details) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023
Convertible Debt
Total convertible debt	$ 9,410,053	$ 9,140,257
Convertible Notes
Convertible Debt
Beginning of year	9,140,257
Proceeds		10,000,000
Deferred financing costs		(1,346,793)
PIK interest	153,686	223,954
Amortization of deferred financing costs	116,110	263,096
End of year	9,410,053	9,140,257
Total convertible debt	$ 9,410,053	$ 9,140,257

XML

Stockholders' Equity - Shares - Tabular Disclosure (Details)	3 Months Ended
	Mar. 31, 2024 Vote $ / shares
Subordinate Voting Shares
Common stock
Common stock, no par value (in dollars per share) | $ / shares	$ 0
Common stock, authorized	Unlimited
Common stock, voting rights	1 vote for each share
Common stock, voting rights, votes per share | Vote	1
Multiple Voting Shares
Common stock
Common stock, no par value (in dollars per share) | $ / shares	$ 0
Common stock, authorized	Unlimited
Common stock, voting rights	100 votes for each share
Common stock, voting rights, votes per share | Vote	100
Super Voting Shares
Common stock
Common stock, no par value (in dollars per share) | $ / shares	$ 0
Common stock, authorized	Unlimited
Common stock, voting rights	1,000 votes for each share
Common stock, voting rights, votes per share | Vote	1,000

XML

Stockholders' Equity - Shares - General Information (Details)	Mar. 31, 2024 Vote shares
Subordinate Voting Shares
Common stock
Common stock, voting rights, votes per share	1
Multiple Voting Shares
Common stock
Common stock, voting rights, votes per share	100
Common stock, convertible, number of shares (in shares) | shares	100
Super Voting Shares
Common stock
Common stock, voting rights, votes per share	1,000
Common stock, convertible, number of shares (in shares) | shares	1

XML

Stockholders' Equity - Shares Issued (Details) - Multiple Voting Shares	3 Months Ended
	Mar. 31, 2024 shares
Stockholders' Equity
Number of shares redeemed	10,342
Number Of Redeemed Shares	1,034,200

XML

Stock-Based Compensation - Stock Options - General Information (Details) - Employee Stock Option	3 Months Ended
	Mar. 31, 2024
Stock-Based Compensation
Percentage of the number of shares outstanding assuming conversion of all super voting shares and multiple voting shares to subordinate voting shares permitted to be issued (as a percent)	10.00%
Percentage of the fair market value of shares on the date of grant (as a percent)	100.00%
Maximum
Stock-Based Compensation
Expiration period	10 years

XML

Stock-Based Compensation - Stock Options - Assumptions (Details) - Employee Stock Option	3 Months Ended
	Mar. 31, 2023 $ / shares
Weighted average assumptions
Risk-Free Interest Rate (as a percent)	3.84%
Weighted Average Exercise Price	$ 0.28
Weighted Average Stock Price	$ 0.17
Expected Life of Options (years)	5 years 10 months 6 days
Expected Annualized Volatility (as a percent)	100.00%
Grant Fair Value	$ 0.13

XML

Stock-Based Compensation - Stock Options - Activity (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Number of Shares
Beginning balance (in shares)	29,969,324	23,547,558
Forfeitures (in shares)	(23,813)	(4,137,079)
Granted (in shares)		10,558,845
Ending balance (in shares)	29,945,511	29,969,324	23,547,558
Weighted Average Exercise Price
Beginning of period (in dollars per share)	$ 0.50	$ 0.66
Forfeitures (in dollars per share)	1.19	0.82
Granted (in dollars per share)		0.25
End of period (in dollars per share)	$ 0.50	$ 0.50	$ 0.66
Additional Information
Weighted average remaining life	5 years 11 months 4 days	6 years 2 months 4 days	7 years 3 months 18 days
Granted		6 years 5 months 1 day
Options exercisable, outstanding (in shares)	24,596,552
Options exercisable, weighted average exercise price (in dollars per share)	$ 0.42
Options exercisable, weighted average remaining life	5 years 6 months 10 days

XML

Stock-Based Compensation - Stock Options - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation expense
Stock-based compensation expense	$ 179,789	$ 1,675,594
Employee Stock Option
Stock-based compensation expense
Stock-based compensation expense	$ 86,732	$ 1,399,258

XML

Stock-Based Compensation - Stock Options - Unrecognized Compensation Costs (Details) - Employee Stock Option	3 Months Ended
	Mar. 31, 2024 USD ($)
Unrecognized compensation costs
Unrecognized compensation costs	$ 416,563
Cost not yet recognized, period for recognition	1 year 8 months 12 days

XML

Stock-Based Compensation - Stock Options - Intrinsic Value (Details)	Mar. 31, 2024 USD ($)
Additional Information
Options outstanding, intrinsic value	$ 3,388,310
Options exercisable, intrinsic value	$ 2,973,949

XML

Stock-Based Compensation - Warrants - General Information and Assumptions (Details)	Mar. 31, 2024 shares
Common Stock Warrants, Equity, Subordinate Voting Share Warrants
Warrants
Warrants, number of shares called by each warrant (in shares)	1
MVS Warrants
Warrants
Warrants, number of shares called by each warrant (in shares)	1

XML

Stock-Based Compensation - Warrants - Outstanding (Details) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Warrants
Granted		6 years 5 months 1 day
SVS Warrants
Warrants
Warrants outstanding, beginning balance (in shares)	16,400,000	150,000
Granted (in shares)		16,250,000
Warrants outstanding, ending balance (in shares)	16,400,000	16,400,000	150,000
Warrants exercisable (in shares)	16,400,000
Weighted average exercise price, beginning of period (in dollars per share)	$ 0.21	$ 1.49
Granted (in dollars per share)		0.20
Weighted average exercise price, end of period (in dollars per share)	0.21	$ 0.21	$ 1.49
Warrants exercisable, weighted average exercise price (in dollars per share)	$ 0.21
Weighted average remaining life	4 years 3 months 25 days	4 years 6 months 25 days	2 years
Granted		5 years
Warrants exercisable, weighted average remaining life	4 years 3 months 25 days
SVS Warrants Denominated
Warrants
Warrants outstanding, beginning balance (in shares)	3,037,649	3,037,649
Warrants outstanding, ending balance (in shares)	3,037,649	3,037,649	3,037,649
Warrants exercisable (in shares)	3,037,649
Weighted average exercise price, beginning of period (in dollars per share)	$ 3.50	$ 3.50
Weighted average exercise price, end of period (in dollars per share)	3.50	$ 3.50	$ 3.50
Warrants exercisable, weighted average exercise price (in dollars per share)	$ 3.50
Weighted average remaining life	1 year 11 months 23 days	2 years 2 months 23 days	3 years 2 months 23 days
Warrants exercisable, weighted average remaining life	1 year 11 months 23 days

XML

Stock-Based Compensation - Warrants - Stock-based Compensation Expense (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Stock-based compensation expense
Exercise price of warrants (in dollars per share)	$ 0.17
Stock-based compensation expense	$ 179,789	$ 1,675,594
Convertible Note
Stock-based compensation expense
Warrants issued	6,250,000
Term of warrants	5 years
Warrants issued in financing activities	$ 497,055
Common Stock Warrants, Equity, Subordinate Voting Share Warrants
Stock-based compensation expense
Stock-based compensation expense	$ 0	$ 0

XML

Stock-Based Compensation - RSU (Details) - USD ($)	3 Months Ended		12 Months Ended	15 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023	Mar. 31, 2024
Stock-Based Compensation
Stock-based compensation expense	$ 179,789	$ 1,675,594
RSUs
Stock-Based Compensation
Vesting Period	3 years
Stock-based compensation expense	$ 93,057		$ 276,336
Number of Shares
Beginning balance (in shares)	2,543,011	3,221,677	3,221,677	3,221,677
Ending balance (in shares)	2,543,011		2,543,011	2,543,011
Vested (in Shares)	1,025,253
Weighted Average Exercise Price
Beginning of period (in dollars per share)	$ 0.88	$ 0.81	$ 0.81	$ 0.81
End of period (in dollars per share)	0.88		$ 0.88	$ 0.88
Vested (in dollars per share)	$ 0.95
Granted on March 15, 2022
Number of Shares
Forfeitures (in Shares)				(678,666)
Weighted Average Exercise Price
Forfeitures (in dollars per share)				$ 0.54

XML

Commitments and Contingencies (Details)			3 Months Ended	12 Months Ended
	May 02, 2024 USD ($)	Oct. 13, 2022 USD ($)	Mar. 31, 2024 item	Dec. 31, 2023 item	Jan. 31, 2022	Feb. 25, 2019 USD ($)
Arrangement Agreement with Verano Holdings Corp
Commitments and Contingencies
Damages sought		$ 14,875,000
Lists of documents served for examination | item			4	4
Filing period				30 days
Arrangement Agreement with Verano Holdings Corp | Subordinate Voting Shares
Commitments and Contingencies
Exchange ratio					0.22652
Arrangement Agreement with Verano Holdings Corp | Multiple Voting Shares
Commitments and Contingencies
Exchange ratio					22.652
Verano
Commitments and Contingencies
Damages sought	$ 869,000,000.0
Schneyer | Minimum
Commitments and Contingencies
Unspecified damages						$ 50,000

XML

Selling, General and Administrative Expenses (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Selling, General and Administrative Expenses
Salaries and benefits	$ 3,512,736	$ 3,797,410
Professional fees	1,427,096	890,167
Insurance expenses	569,185	635,439
Marketing	222,014	225,113
Other expenses	1,320,582	1,608,706
Total	$ 7,051,613	$ 7,156,835

XML

Other Income (Expense) (Details)		3 Months Ended
	May 25, 2023 shares	Mar. 31, 2024 USD ($) Y $ / shares	Dec. 31, 2023 USD ($)
Unusual Risk or Uncertainty [Line Items]
Exercise price of warrants (in dollars per share) | $ / shares		$ 0.17
Warrants held | $		$ 3,265,231	$ 1,937,352
Warrants Value Recognized As Other Income | $		$ 1,327,879
Share price
Unusual Risk or Uncertainty [Line Items]
Warrants, measurement input | $ / shares		0.45
Measurement Input, Expected Term
Unusual Risk or Uncertainty [Line Items]
Warrants, measurement input | Y		4.52
Measurement Input, Risk Free Interest Rate
Unusual Risk or Uncertainty [Line Items]
Warrants, measurement input		4.21
Measurement Input, Option Volatility
Unusual Risk or Uncertainty [Line Items]
Warrants, measurement input		100
Grown Rogue International Inc. [Member]
Unusual Risk or Uncertainty [Line Items]
Warrants Issuable Under Agreement | shares	8,500,000

XML

Supplemental Cash Flow Information (Details) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Supplemental Cash Flow Information
Cash paid for interest	$ 6,799,193	$ 5,731,120
Change in construction accrued expenses	$ (121,433)

XML

Financial Instruments (Details)	3 Months Ended
	Mar. 31, 2024 USD ($)
Financial Instruments
Effect on net income of 100 basis point change in US prime rate	$ 138,570

XML

Related Party Transactions (Details) - USD ($)	Mar. 31, 2024	Dec. 31, 2023
Related Party Transactions
Due to related parties	$ 0	$ 121,846

XML

Subsequent Events (Details) - USD ($)	May 02, 2024	Apr. 01, 2024	Feb. 22, 2024
Cannabis cultivation and manufacturing facilities located in Elk River, Minnesota
Subsequent Events
Initial purchase price, amount			$ 13,000,000
Initial purchase price, percentage			3.00%
Verano
Subsequent Events
Damages sought	$ 869,000,000.0
Subsequent Event | ACE Ventures LLC
Subsequent Events
Unsecured loan		$ 2,500,000
Subsequent Event | Minimum | ACE Ventures LLC
Subsequent Events
Expected purchase price		3,000,000.0
Subsequent Event | Maximum | ACE Ventures LLC
Subsequent Events
Expected purchase price		5,000,000.0
Subsequent Event | Eighth amendment
Subsequent Events
Initial purchase price, amount		$ 81,000,000
Initial purchase price, percentage		3.00%